NEW LIMITATION CHANGE

TO

Approved for public release, distribution unlimited

FROM

Distribution authorized to U.S. Gov't. agencies only; Proprietary Info; May 99 Other requests shall be referred to USAMRMC, Ft Detrick, MD 21702-5012

AUTHORITY

USAMRMC ltr, dtd 21 Feb 2003

Award Number DAMD17 - 98-1-8133

TITLE: Toward a New Chemotherapy for Breast Cancer: Structural and Functional Mechanism of the Retinoid Receptors Addressed by a Novel Computer Approach

PRINCIPAL INVESTIGATOR: Ruben A. Abagyan, Ph.D.

CONTRACTING ORGANIZATION: New York University Medical Center
New York, New York 10016

REPORT DATE: May 1999

TYPE OF REPORT: Annual

PREPARED FOR: U.S. Army Medical Research and Materiel Command
Fort Detrick, Maryland 21702-5012

DISTRIBUTION STATEMENT: Distribution authorized to U.S. Government Agencies Only (proprietary information, May 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.

The views, opinions and/or findings contained in this report are those of the author(s) and should not be construed as an official Department of the Army position, policy or decision unless so designated by other documentation.

NOTICE

USING GOVERNMENT DRAWINGS, SPECIFICATIONS, OR OTHER DATA INCLUDED IN THIS DOCUMENT FOR ANY PURPOSE OTHER THAN GOVERNMENT PROCUREMENT DOES NOT IN ANY WAY OBLIGATE THE U.S. GOVERNMENT. THE FACT THAT THE GOVERNMENT FORMULATED OR SUPPLIED THE DRAWINGS, SPECIFICATIONS, OR OTHER DATA DOES NOT LICENSE THE HOLDER OR ANY OTHER PERSON OR CORPORATION; OR CONVEY ANY RIGHTS OR PERMISSION TO MANUFACTURE, USE, OR SELL ANY PATENTED INVENTION THAT MAY RELATE TO THEM.

LIMITED RIGHTS LEGEND

Award Number: DAMD17-98-1-8133
Organization: New York University Medical Center

Those portions of the technical data contained in this report marked as limited rights data shall not, without the written permission of the above contractor, be (a) released or disclosed outside the government, (b) used by the Government for manufacture or, in the case of computer software documentation, for preparing the same or similar computer software, or (c) used by a party other than the Government, except that the Government may release or disclose technical data to persons outside the Government, or permit the use of technical data by such persons, if (i) such release, disclosure, or use is necessary for emergency repair or overhaul or (ii) is a release or disclosure of technical data (other than detailed manufacturing or process data) to, or use of such data by, a foreign government that is in the interest of the Government and is required for evaluational or informational purposes, provided in either case that such release, disclosure or use is made subject to a prohibition that the person to whom the data is released or disclosed may not further use, release or disclose such data, and the contractor or subcontractor or subcontractor asserting the restriction is notified of such release, disclosure or use. This legend, together with the indications of the portions of this data which are subject to such limitations, shall be included on any reproduction hereof which includes any part of the portions subject to such limitations.

THIS TECHNICAL REPORT HAS BEEN REVIEWED AND IS APPROVED FOR PUBLICATION.

_____   _____

_____   _____

1. AGENCY USE ONLY *(Leave blank)*	2. REPORT DATE May 1999	3. REPORT TYPE AND DATES COVERED Annual (1 May 98 - 30 Apr 99)	
4. TITLE AND SUBTITLE Toward a New Chemotherapy for Breast Cancer: Structural and Functional Mechanism of the Retinoid Receptors Addressed by a Novel Computer Approach		5. FUNDING NUMBERS DAMD17-98-1-8133	
6. AUTHOR(S) Ruben A. Abagyan, Ph.D.			
7. PERFORMING ORGANIZATION NAME(S) AND ADDRESS(ES) New York University Medical Center New York, New York 10016		8. PERFORMING ORGANIZATION REPORT NUMBER	
9. SPONSORING / MONITORING AGENCY NAME(S) AND ADDRESS(ES) U.S. Army Medical Research and Materiel Command Fort Detrick, Maryland 21702-5012		10. SPONSORING / MONITORING AGENCY REPORT NUMBER	
11. SUPPLEMENTARY NOTES			
12a. DISTRIBUTION / AVAILABILITY STATEMENT Distribution authorized to U.S. Government Agencies Only (proprietary information, May 99). Other requests for this document shall be referred to U.S. Army Medical Research and Materiel Command, 504 Scott Street, Fort Detrick, Maryland 21702-5012.		12b. DISTRIBUTION CODE	

13. ABSTRACT *(Maximum 200 words)*

Retinoids are known to be potent inhibitors of the proliferation of breast cancer cells, and recent observations have showed that they could be efficient molecular tools for breast cancer therapy. Our purpose is to help understand and control the activity of retinoid receptors, in order to design a new generation of drugs, more selective and efficacious, for breast cancer prevention and treatment. From a model of the active form of the Retinoid X Receptor (RXR), we could derive the determinants for retinoid receptor selectivity. We were then able to predict the mode of interaction between the Retinoic Acid Receptor (RAR) or RXR and known ligands. We also modeled the interaction between RAR or RXR and NRIF3, a novel nuclear receptor coactivator. Eventualy, we discovered three novel agonists and two novel antagonists of RAR, which could lead to new drugs against breast cancer.

14. SUBJECT TERMS Breast Cancer – Retinoid Receptors – Structure – Computer Modeling – Drug Design – Agonist – Antagonists			15. NUMBER OF PAGES 90
			16. PRICE CODE
17. SECURITY CLASSIFICATION OF REPORT Unclassified	18. SECURITY CLASSIFICATION OF THIS PAGE Unclassified	19. SECURITY CLASSIFICATION OF ABSTRACT Unclassified	20. LIMITATION OF ABSTRACT limited

NSN 7540-01-280-5500

Standard Form 298 (Rev. 2-89)
Prescribed by ANSI Std. Z39-18 298-102

USAPPC V1.00

FOREWORD

Opinions, interpretations, conclusions and recommendations are those of the author and are not necessarily endorsed by the U.S. Army.

_____ Where copyrighted material is quoted, permission has been obtained to use such material.

_____ Where material from documents designated for limited distribution is quoted, permission has been obtained to use the material.

_____ Citations of commercial organizations and trade names in this report do not constitute an official Department of Army endorsement or approval of the products or services of these organizations.

_√_ In conducting research using animals, the investigator(s) adhered to the "Guide for the Care and Use of Laboratory Animals," prepared by the Committee on Care and use of Laboratory Animals of the Institute of Laboratory Resources, national Research Council (NIH Publication No. 86-23, Revised 1985).

_____ For the protection of human subjects, the investigator(s) adhered to policies of applicable Federal Law 45 CFR 46.

_√_ In conducting research utilizing recombinant DNA technology, the investigator(s) adhered to current guidelines promulgated by the National Institutes of Health.

_√_ In the conduct of research utilizing recombinant DNA, the investigator(s) adhered to the NIH Guidelines for Research Involving Recombinant DNA Molecules.

_____ In the conduct of research involving hazardous organisms, the investigator(s) adhered to the CDC-NIH Guide for Biosafety in Microbiological and Biomedical Laboratories.

_____   5|19|99
PI - Signature   Date

Table of Contents

Introduction

Retinoids, natural and synthetic derivatives of vitamin A, are known to be potent inhibitors of the proliferation of breast cancer cells (Budd et al, Fitzgerald et al., Giannini et al.). Retinoids, as well as Tamoxifen, the molecular compound of choice used in hormone-dependent breast cancer chemotherapy, regulate the transcriptional activation pathway mediated by specific nuclear hormone receptors. The recent observation that they could be efficient molecular tools for breast cancer treatment has lead to an explosion of information concerning the mechanism of action of these molecules (Moras and Gronemeyer for review). It is now clear that understanding and controlling the activity of retinoid receptors will enable the design of a new generation of drugs, more selective and efficacious, for breast cancer prevention and treatment. Our goal is to use computer modeling to identify the structural determinants of retinoids which confer them their receptor selectivity and their agonist or antagonist activity, and rationally design molecules with various affinity for the Retinoic Acid Receptors (RARs) and the Retinoid X Receptors (RXRs).

Body

Research accomplishment associated with each task outlined in the statement of work:

Task 1: Identify the structural determinants which confer a ligand RXR or RAR selectivity

1-Predict the structure of RAR-Ligand Binding Domain (RAR-LBD) bound to 9-cis Retinoic Acid (9-cis RA):

We used the structure of RAR-LBD bound to All-Trans Retinoic Acid (All-Trans RA) to dock 9-cis RA into the ligand binding pocket of the receptor. Both the ligand and the receptor side-chains were flexible in our improved docking algorithm (Totrov and Abagyan), and the resulting model could be used for the next step.

2-Model the structure of RXR-LBD bound to 9-cis RA:

We used the crystal structure of unliganded RXR and the result from step 1 to model by homology the RXR-LBD/9-cis RA complex (figure 1). We came to the unexpected finding that the overall shape of the RXR binding pocket is shorter and bulkier than the RAR ligand binding pocket. This result shows that All-Trans RA is RAR selective because it is too long for the RXR binding pocket.

3-Dock RXR- and RAR-selective ligands into the receptors pocket:

9-cis RA (RAR and RXR specific), All-Trans RA (RAR selective), BMS961 (RAR selective) and Targretin (RXR selective) were docked into the binding pocket of RAR-LBD (crystal structure) and RXR-LBD (model), and the complexes were relaxed according to an extensive energy minimization procedure. The Van der Waals

interactions (Gvw) between the receptors and ligands were then calculated. Figure 2 shows that, for each of the eight complexes, the calculated Gvw was negative when the ligand experimentally did bind the receptor, and was positive when the ligand experimentally did not bind the receptor. This perfect correlation between the models and the experiments was an encouraging indication of the validity of our approach.

4-Identify the functional groups of the ligands responsible for their affinity either for RXR or for RAR:

The results from step 3 show that the overall shape of the binding pocket determines the specificity of interaction, more than the network of hydrogen-bond donors and acceptors. Indeed, the fact that the Van der Waals term correlates with the affinity of the ligands for the receptors indicates that steric parameters are the critical receptor selectivity. Figure 2 shows for each ligand which is/are the functional group(s) sticking out of the binding pocket and responsible for Van der Waals clash.

Task 2: Identify the structural properties a ligand must satisfy to be an agonist

The original strategy was to model the interaction between RXR and the TATA binding protein (TBP), which is believed to be a coactivator. Important data regarding the identification, activity and structure of nuclear receptor coactivators has been published since (L. Freeman for review), which enabled us to refine our approach: upon binding of an agonist, the LBD undergoes a conformational change, which generates a hydrophobic pocket at its surface. This hydrophobic pocket is in turn the binding site for a conserved LxxLL motif of coactivator proteins. On the other hand, antagonists are believed to disrupt the formation of the hydrophobic pocket, and thus prevent complexation of coactivators to the receptor.

We collaborated with Dr Herbert Samuel's lab, at NYU Medical Center, to identify a novel coactivator, NRIF3, mediating functional specificity of nuclear hormone receptors. This novel protein coactivates RXR but not RAR. The manuscript presenting this work was submitted for publication, but is not published yet; it is therefore confidential, and appended to this report. Our modeling suggests that NRIF3 binds to liganded receptors through an LxxIL module contained within its C-terminal domain.

Task 3: Design rationally and test novel drugs against breast cancer

1-Use our model to screen libraires of compounds and select ligands with desired structural characteristics:

We plan to design novel agonists and antagonists for both RAR and RXR, and test them. We first applied our virtual screening algorithm to find RAR agonists and antagonists. Our approach to find antagonists was very innovative: we modeled the receptor in its inactive conformation, using as a template the crystal structure of the estrogen receptor bound to Tamoxifen, and used the resulting model to discover antagonists. The second confidential manuscript appended to this report describes more in detail this work.

2-Test the ligand candidates *in vitro*

Activity tests were performed and showed that we discovered three novel RAR agonists and two novel RAR specific antagonists. Some of the compounds discovered are very different from any RAR ligand described so far and could lead to novel drugs against breast cancer. The manuscript appended to this report is not published yet and these results are confidential.

3-Test these ligands *in vivo* for their efficacy against rat mammary tumor:

These tests remain to be done.

Key research accomplishments

-We built a model of the active conformation of RXR

-We determined the structural differences between the RAR and RXR binding pockets, responsible for ligand selectivity.

-We modeled the interaction between known ligands and RAR or RXR and observed a very good correlation between our models and biochemical data.

-We modeled the interaction between RAR or RXR and NRIF3, a novel nuclear receptor coactivator.

-We discovered novel RAR agonists.

-We discovered novel RAR antagonists.

Reportable outcomes

-Manuscript 1, confidential, submitted to *Molecular and Cellular Biology:*
NRIF3 is novel co-activator mediating functional specificity of nuclear hormone receptors.
D. Li, V. Desai-Yajnik, E. Lo, M. Schapira, R. Abagyan, and H. Samuels

-Manuscript 2, confidential, to be submitted to *Nature Medicine:*
Rational design of novel Nuclear Hormone Receptors
M. Schapira, B. Raaka, H. Samuels, and R. Abagyan

Conclusions

During the first year of our efforts, we have already accomplished many of the tasks outlined in the approved Statement of Work. Many structural models were built, which showed very good correlation with available biochemical data, and shed some light on the specificity of interaction between the retinoid receptors and their ligands.

Our approach regarding the structural properties a ligand must satisfy to be an agonist was modified in view of important data recently published, and we could build a model which explains how, upon binding of an agonist to the receptor, a novel protein can activate selectively RXR.

We also were able to develop a strategy to rationally design antagonists, as well as agonists, for RAR. The activity of these novel molecules were confirmed *in vitro*.

"So what" section:

The relevance of our work was outlined by the discovery of novel agonists and antagonists of RAR. These molecules need now to be further optimized and their activity further characterized. We also need to conduct the same approach on the model of RXR that we built.

Our effort is therefore already contributing to a better understanding and control of the mechanism of retinoid receptors, and hopefully will enable the design of a new generation of drugs, more selective and efficacious, for breast cancer prevention and treatment.

References

Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. *Clin Cancer Res* 1998 Mar;4(3):635-42

Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. *Cancer Res* 1997 Jul 1;57(13):2642-50

Freeman L. Increasing the complexity of coactivation in nuclear receptor signaling. *Cell* 1999 Apr. 2, 97:5-8

Giannini G, Dawson MI, Zhang X, Thiele CJ. Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells. *J Biol Chem* 1997 Oct 17;272(42):26693-701

Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. *Curr Opin Cell Biol* 1998 Jun;10(3):384-91

Totrov M, Abagyan R. Detailed ab initio prediction of lysozyme-antibody complex with 1.6 A accuracy. *Nat Struct Biol* 1994 Apr;1(4):259-63

Appendices

All-Trans RA in the RAR binding pocket
(crystal structure)


9-cis RA in the RXR binding pocket
(Model)

Figure 1: Crystal structure and model of retinoids in the binding pocket of the receptors. The Van der Waals boundary of the receptor is yellow.

Figure 2: Known ligands docked into RAR and RXR. Complexes indicated in green are stable, in red are unstable (biochemical experiment). Gvw = calculated Van der Waals interaction (in kcal/mol)

NRIF3 is a novel co-activator mediating functional specificity of nuclear hormone receptors

Dangsheng Li[1], Vandana Desai-Yajnik[1], Eric Lo[1], Matthieu Schapira[2], Ruben Abagyan[2], and Herbert H. Samuels[1,3]

[1]Division of Molecular Endocrinology, Departments of Medicine and Pharmacology

[2]Structural Biology, Skirball Institute of Biomolecular Medicine

New York University School of Medicine

550 First Avenue

New York, NY 10016 USA

[3]To whom correspondence should be addressed.

Tel: 212-263-6279

Fax: 212-263-7701

E-mail: samueh01@mcrcr.med.nyu.edu (HHS)

Abstract

Many nuclear receptors are capable of recognizing similar DNA elements. The molecular event(s) underlying the functional specificity of these receptors (in regulating the expression of their native target genes) is a very important question that remains poorly understood. Here we report the cloning and analysis of a novel nuclear receptor co-activator (designated as NRIF3) that exhibits a distinct receptor specificity. Fluorescence microscopy shows that NRIF3 localizes to the cell nucleus. Yeast two-hybrid and / or *in vitro* binding assays indicate that NRIF3 specifically interacts with TR (thyroid hormone receptor) and RXR (retinoid X receptor) in a ligand-dependent fashion, but does not bind to RAR (retinoic acid receptor), VDR (vitamin D receptor), PR (progesterone receptor), GR (glucocorticoid receptor), or ER (estrogen receptor). Functional studies show that NRIF3 significantly potentiates TR- and RXR-mediated transactivation *in vivo* while little effect is observed for other examined nuclear receptors. Domain and mutagenesis analyses indicate that a novel C-terminal domain in NRIF3 plays an essential role in its specific interaction with liganded TR and RXR, while the N-terminal LxxLL motif plays a minor role in allowing optimum interaction. Computer modeling suggests that NRIF3 binds to liganded receptors through an LxxIL module contained within its C-terminal domain, where the combination of hydrophobic and electrostatic interactions generate receptor specificity. The identification of a co-activator with such a unique receptor specificity provides new insight into the molecular mechanism(s) of receptor-mediated transcriptional activation as well as the functional specificity of nuclear receptors.

Introduction

Nuclear hormone receptors are ligand-regulated transcription factors that play diverse roles in cell growth, differentiation, development, and homeostasis. The nuclear receptor superfamily has been divided into two sub-families: the steroid receptor family and the thyroid hormone / retinoid (nonsteroid) receptor family (for a review, see Mangelsdorf et al. 1995). The steroid receptor family includes receptors for glucocorticoids (GR), mineralcorticoids (MR), progestins (PR), androgens (AR) and estrogens (ERs) (Mangelsdorf, et al. 1995). The nonsteroid receptor family includes receptors for thyroid hormones (TRs), retinoids (RARs and RXRs), 1,25-(OH)$_2$ vitamin D (VDR), prostanoids (PPARs) as well as many orphan receptors whose ligands (if any) remain to be defined (for reviews, see Mangelsdorf and Evans 1995; Mangelsdorf, et al. 1995). Members of the nuclear receptor superfamily share common structural and functional motifs. Nevertheless, an important difference exists between the two sub-families. Steroid receptors primarily act as homodimers by binding to their cognate palindromic hormone response elements (HREs) (Umesono and Evans 1989; Umesono et al. 1991). In contrast, members of the nonsteroid receptor family can bind to DNA as monomers, homodimers, and heterodimers (Umesono, et al. 1991; Forman et al. 1992). Their corresponding HREs are also complex, and can be organized as direct repeats, inverted repeats, and everted repeats (Mangelsdorf and Evans 1995). Therefore, the combination of heterodimerization and HRE complexity provides the potential to generate enormous diversity in receptor-mediated regulation of target gene expression.

Structural and functional studies indicate that the ligand binding domain (LBD) of many members of the thyroid hormone / retinoid receptor family harbors diverse functions. In addition to ligand binding, the LBD also plays roles in mediating receptor dimerization, hormone-dependent transactivation, and in the case of TR and RAR, ligand-relieved gene silencing (Nagpal et al. 1993; Qi et al. 1995). The carboxyl-terminal helix of the LBD has been implicated in playing an important role in ligand-dependent conformational changes and transactivation (Barettino et al. 1994; Durand et al. 1994; Baniahmad et al. 1995; Leng et al. 1995). Although it has been suggested that an activation function (AF-2) resides in this C-terminal helix, recent studies indicate

16

that AF-2 results from a ligand-induced conformational change involving diverse areas of the LBD (Feng et al. 1998; Selmi-Ruby et al. 1998). Thus, ligand binding serves to switch the receptor from one functional state (e.g. inactive or silencing) to another (e.g. transactivation).

Although much has been learned from studying the structure and function of these receptors, the detailed molecular mechanism(s) of transcriptional regulation by these receptors is not well understood. Efforts to understand the molecular mechanism of transcriptional repression by unliganded TRs and RARs have led to the description (Casanova et al. 1994) and isolation of putative co-repressor proteins SMRT and N-CoR, which interact with the LBD of these receptors in the absence of their ligands (Chen and Evans 1995; Horlein et al. 1995). The recent discovery that both SMRT and N-CoR form complexes with Sin3 and a histone deacetylase suggests that chromatin remodeling by histone deacetylation may play a role in receptor-mediated transcriptional repression (Heinzel et al. 1997; Nagy et al. 1997).

In a somewhat parallel approach, the identification of co-activators has recently received extensive experimental attention in order to elucidate the molecular mechanism(s) of transcriptional activation by nuclear receptors (for a review, see Glass et al. 1997). Identified co-activator proteins primarily belong to two groups: the SRC-1 family and the CBP/p300 family. The SRC-1 family includes SRC-1/NCoA-1 (Onate et al. 1995; Kamei et al. 1996; Torchia et al. 1997), and the related proteins GRIP1/TIF2/NCoA-2 (Hong et al. 1996; Voegel et al. 1996; Hong et al. 1997; Torchia, et al. 1997), and AIB1/p/CIP/ACTR/RAC3/TRAM-1 (Anzick et al. 1997; Chen et al. 1997; Li et al. 1997; Takeshita et al. 1997; Torchia, et al. 1997). The second group of co-activators includes CBP and its homolog p300, which not only influence the activity of nuclear receptors (Chakravarti et al. 1996; Hanstein et al. 1996; Kamei, et al. 1996), but also functionally interact with many transcription factors such as CREB (Chrivia et al. 1993; Kwok et al. 1994; Arany et al. 1995; Lundblad et al. 1995), the Stats (Bhattacharya et al. 1996; Zhang et al. 1996), AP1 (Arias et al. 1994; Bannister and Kouzarides 1995), and p53 (Gu et al. 1997; Lill et al. 1997). There are also co-activator proteins that do not belong to these two groups, such as ARA70 (Yeh and Chang 1996), and PGC-1 (Puigserver et al. 1998). Members of both the SRC-1 family and

17

CBP/p300 family have been shown to possess histone acetyltransferase (HAT) activities (Bannister and Kouzarides 1996; Ogryzko et al. 1996; Chen, et al. 1997; Spencer et al. 1997), suggesting that chromatin remodeling by histone acetylation is an important mechanism involved in transcriptional activation by ligand-bound nuclear receptors.

Interaction of members of the SRC-1 and CBP/p300 families with nuclear receptors occurs through conserved LxxLL motifs (Heery et al. 1997), which interact with a hydrophobic cleft in the receptor LBD formed as a result of conformational changes mediated by ligand binding (Darimont et al. 1998; Feng, et al. 1998; Nolte et al. 1998). SRC-1/NCoA-1 and GRIP1/TIF2 contain three LxxLL regions or boxes (referred to as LXDs or NR boxes) that differentially interact with nuclear receptors so that different nuclear receptors functionally utilize different LxxLL boxes (Darimont, et al. 1998; McInerney et al. 1998). Thus, ER utilizes the second LxxLL box of SRC-1/NCoA-1 while PR utilizes both the first and second LxxLL boxes for optimal interaction. In contrast, TR and RAR require both the second and third LxxLL boxes for optimal interaction (McInerney, et al. 1998). The specificity of receptor recognition by the different LxxLL boxes of SRC-1/NCoA-1 is primarily mediated by eight amino acid residues C-terminal to the LxxLL motif rather than by the two amino acids (xx) within the motif itself. Thus, while members of the SRC-1 family are capable of interacting with many nuclear receptors, the molecular detail of such interactions differs for each receptor in the number or combination of LxxLL boxes utilized as well as in the critical amino acid residues surrounding the LxxLL motifs.

While much has been learned from the study of known co-activators, a number of key mechanistic questions remain to be answered. For example, many nuclear receptors can recognize common DNA elements (Forman, et al. 1992; Mangelsdorf and Evans 1995; Mangelsdorf, et al. 1995), while not all are capable of regulating genes containing those elements (Schule et al. 1990; Desai-Yajnik and Samuels 1993; MacDonald et al. 1993). Thus, how native target genes containing such elements are selectively regulated by specific receptors is a very important but poorly-understood problem. Although the various LxxLL boxes of SRC-1 and GRIP1 show differential receptor preference (Darimont, et al. 1998; McInerney, et al. 1998), these co-activators

18

are unlikely to play a primary role in mediating effects that are receptor specific since they appear to interact with all ligand-bound nuclear hormone receptors. Thus, the detailed molecular mechanism(s) underlying receptor-specific regulation of gene expression remains to be elucidated. Whether co-activator(s) might contribute to this specificity is currently unknown.

To further our understanding of the molecular events underlying receptor-activated transcription, we sought to identify additional co-activators using a yeast two-hybrid screening strategy (Gyuris et al. 1993). In this paper, we report the isolation of a novel co-activator for nuclear receptors, designated as NRIF3. Fluorescence microscopy indicates that NRIF3 is a nuclear protein. The yeast two-hybrid and *in vitro* binding assays revealed that NRIF3 interacts specifically with TR and RXR in a ligand-dependent fashion but does not interact with other examined nuclear receptors. Transfection studies indicate that NRIF3 selectively potentiates TR- and RXR-mediated transactivation *in vivo*. NRIF3 encodes a small protein of 177 amino acids and other than an N-terminal LxxLL motif shares no homology with known co-activators. Domain analysis and computer modeling suggest that the receptor specificity of NRIF3 is mediated through a novel C-terminal domain that contains an LxxIL module. These findings provide novel insights into the molecular mechanism(s) of receptor-mediated transcriptional activation as well as the functional specificity of nuclear receptors.

Results

Cloning of the NRIF3 cDNA

To isolate potential co-activators mediating the transcriptional activation function of nuclear receptors, we employed a yeast two-hybrid screening strategy (Gyuris, et al. 1993). A bait expressing a full length TRα fused to the C-terminus of the LexA DNA binding domain was used to screen a HeLa cell cDNA library cloned into pJG4-5 (Gyuris, et al. 1993). Candidate clones that exhibited a thyroid hormone (T3)-dependent interaction with LexA-TRα were selected and further examined and sequenced. Four novel clones were identified and all were found to exhibit similar interaction with the ligand binding domain (LBD) of TRα as with full length receptor (data

19

not shown). These clones were designated as NRIF1, 2, 3 and 4 (Nuclear receptor interacting factors). Not surprisingly, the LBD of TRβ was also found to interact with these NRIFs in a T3-dependent manner (data not shown). Among these four isolated NRIFs, NRIF3 was a full length clone. As shown in Figure 1, LexA alone (negative control) does not interact with NRIF3 (as indicated by the low β-galactosidase activity) and incubation with T3 has no effect. Similarly, no interaction was detected between the LexA-TR LBD and B42 alone with or without T3 (data not shown). The LexA-TR LBD also shows little interaction with NRIF3 in the absence of T3. However, incubation with T3 results in strong stimulation of the NRIF3-TR LBD interaction (Fig. 1). The extent of T3-dependent interaction between NRIF3 and LexA-TR LBD was similar to that of Trip1 (Fig. 1), one of the first thyroid hormone receptor interacting factors cloned using a two-hybrid screen (Lee et al. 1995).

Sequence analysis of NRIF3

Sequence analysis of the NRIF3 cDNA revealed a single open reading frame (ORF) encoding a polypeptide of 177 amino acids (Fig. 2). NRIF3 shares no homology with members of the SRC-1 and CBP/p300 families. The size of NRIF3 is in sharp contrast to the size of CBP/p300 (around 300 kd), or the SRC-1 family (around 160 kd). NRIF3 contains a putative nuclear localization signal (KRKK), as well as one copy of an LxxLL motif (amino acids 9-13) that was recently identified to be essential for the interaction of a number of putative co-activators with nuclear receptors (Heery, et al. 1997).

A database search identified two highly-related homologs of NRIF3, which were previously designated as β3-endonexin short form and long form (Shattil et al. 1995). The endonexin short form (EnS) was originally isolated from a two-hybrid screen intended to clone factors that interact with the cytoplasmic tail of integrin β3 (Shattil, et al. 1995). The long form (EnL) was then identified as an alternatively spliced product of the same gene. However, the long form does not bind to integrin β3 (Shattil, et al. 1995). Nucleotide sequence comparisons between cDNAs of NRIF3 and endonexin short or long forms indicate that NRIF3 is a third alternatively

20

spliced product of the same gene (alignment not shown). The precise function(s) of the two endonexin proteins is currently under investigation (S. Shattil, personal communication, also see discussion later).

NRIF3 localizes to the cell nucleus

Although a putative nuclear localization signal was found in NRIF3, we considered it important to identify the subcellular location of the NRIF3 protein since extensive homology was found between NRIF3 and the two endonexins. The entire NRIF3 ORF was fused to the C-terminus of green fluorescent protein (GFP) (Cormack et al. 1996). The resulting GFP-NRIF3 fusion protein was expressed in HeLa cells by transient transfection and the subcellular location of the fusion protein was visualized by fluorescence-microscopy. As shown in Figure 3, the control GFP protein is distributed throughout the cell while GFP-NRIF3 is localized exclusively to the nucleus. This result suggests that NRIF3 is a nuclear protein, which is compatible with its putative role as a nuclear receptor co-activator.

Selective interaction of NRIF3 with liganded nuclear receptors in yeast

Although NRIF3 was originally cloned using full length TRα as the bait, we later identified that the region of the receptor responsible for NRIF3 binding is its LBD (see Fig. 1). A common feature among most of the known co-activators that show ligand-dependent interaction with nuclear receptors is the presence of the LxxLL motif(s) in their receptor interaction domains. The LxxLL motif appears to be involved in direct contact with a structurally-conserved surface in the ligand-bound LBDs of the receptors (Feng, et al. 1998), which may provide the molecular basis for the broad spectrum of receptor binding by co-activators such as SRC-1 or GRIP1. Since a putative LxxLL motif is also present in NRIF3 (amino acids 9-13), we asked whether NRIF3 also interacts with the LBDs of other nuclear receptors.

The LBDs of several nuclear receptors were examined for interaction with NRIF3 in a yeast two hybrid assay. As shown in Table 1, NRIF3 does not interact with LexA alone (negative

21

control) with (+) or without (-) ligand. LexA-TR and LexA-RXR show little (if any) interaction with NRIF3 in the absence of their cognate ligands. However, the presence of T3 (for TR) or 9-cis RA (for RXR) results in a strong stimulation of their interaction with NRIF3, as indicated by the induction of β-galactosidase activity (Table 1). Interestingly, when LexA-RAR or LexA-GR was used as the bait, no interaction was detected with NRIF3 in the presence or absence of their cognate ligands (Table 1). The finding that NRIF3 interacts with TR but not RAR was surprising in light of a recent study, which shows that TR and RAR functionally interact with the same LxxLL boxes (boxes 2 and 3) of SRC-1/NCoA-1 (McInerney, et al. 1998). As positive controls, we confirmed that both LexA-RAR and LexA-GR exhibited ligand-dependent interaction with other co-activators that are not receptor-specific (data not shown). Taken together, these results suggest that NRIF3 exhibits differential specificity in its interaction with different nuclear receptors.

NRIF3 specifically binds to TR and RXR but not to other nuclear receptors in vitro

To further examine the interaction between NRIF3 and various nuclear receptors as well as to confirm the potential receptor specificity of NRIF3, *in vitro* GST binding assays were performed (Hadzic et al. 1995). ^{35}S-labeled nuclear receptor, generated by *in vitro* transcription / translation, was incubated with purified GST-NRIF3 or the GST control bound to glutathione-agarose beads. All binding assays were carried out with (+) or without (-) the cognate ligand of the examined receptor. As shown in Figure 4 (top left), TR and NRIF3 interact poorly in the absence of T3. Addition of T3 results in a strong increase in TR binding to GST-NRIF3, confirming that NRIF3 associates with TR in a T3-dependent manner. Using similar binding assays, we also studied the interaction of NRIF3 with six other nuclear receptors. Consistent with our findings from the yeast two-hybrid studies (Table 1), NRIF3 interacts with RXR *in vitro* in a ligand-dependent manner (Fig. 4), but shows little or no binding to other nuclear receptors (RAR, VDR, GR, PR, and ER) in the presence or absence of their cognate ligands (Fig. 4). Taken together, the results of the

yeast two-hybrid (Table 1) and the *in vitro* binding (Fig. 4) assays suggest that NRIF3 possesses a distinct receptor specificity.

NRIF3 selectively potentiates TR- and RXR-mediated transactivation in vivo

To examine the potential role of NRIF3 in TR-mediated transactivation, transfection studies were carried out. HeLa cells, which lack endogenous TR (Forman, et al. 1992), were transfected with a vector expressing TR, and a CAT reporter under the control of the ΔMTV basal promoter linked to an idealized inverted repeat (IR) (AGGTCATGACCT) TRE sequence (IR-ΔMTV-CAT) (Forman, et al. 1992), along with either a control plasmid or a vector expressing NRIF3. As shown in Figure 5A, NRIF3 significantly enhances TR-mediated activation of the CAT reporter (typically 2.5- to 3-fold). As a control, we also examined the effect of CBP, a reported co-activator for nuclear receptors (Chakravarti, et al. 1996; Kamei, et al. 1996), and found that its expression results in a similar degree of enhancement as with NRIF3 (around 3-fold) (Fig. 5A).

We also examined another CAT reporter controlled by the Herpes virus thymidine kinase (tk) promoter linked to native rat growth hormone (GH) TRE sequences (Au-Fliegner et al. 1993). NRIF3 was found to also enhance TR-mediated activation of this reporter (about 3.5-fold) (Fig. 5B). In addition, using similar transfection assays, we found that NRIF3 enhances TR-mediated activation of two other reporters, (IR)2-TATA-CAT and DR4-ΔMTV-CAT (data not shown). Therefore, NRIF3 potentiates TR-mediated transactivation in a variety of different TRE / promoter contexts. Taken together, the results of these transfection studies suggest that NRIF3 can function as a co-activator of TR.

To examine whether NRIF3 can also act as a co-activator for RXR, HeLa cells were transfected with the IR-ΔMTV-CAT reporter, whose IR sequence can also function as a strong response element for the RXR(s) and RAR(s) (Forman, et al. 1992; Mangelsdorf and Evans 1995; Qi, et al. 1995). HeLa cells express endogenous RXR(s) and RAR(s), as the activity of the IR-ΔMTV-CAT reporter is strongly stimulated by their cognate ligands, even without co-transfection of any receptor expression plasmid (Fig. 6A, panels 1, 3, and 5). Co-transfection of NRIF3

enhances the activation of this reporter by either 9-cis RA, or LG100153 (Sugawara et al. 1997),

an RXR-specific ligand (Fig. 6A, panels 1 and 2; 3 and 4). In contrast, although the RAR-specific

ligand TTNPB (Sheikh et al. 1994) also activates the IR-ΔMTV-CAT reporter, co-transfection of

NRIF3 has no effect (Fig. 6A, panels 5 and 6). These results indicate that NRIF3 potentiates the

activity of endogenous RXR(s) but not RAR(s), which is consistent with the distinct receptor

specificity of NRIF3 revealed from the yeast two-hybrid assay (Table 1) and *in vitro* binding

studies (Fig. 4).

To further document that NRIF3 can function as a co-activator for RXR, a vector

expressing exogenous RXR was co-transfected with IR-ΔMTV-CAT. Exogenous RXR

expression enhances the activation of this CAT reporter by either 9-cis RA or LG100153

(comparing Fig. 6B and 6A, panels 1 and 3). This RXR-mediated activation of reporter

expression is further stimulated by NRIF3 (Fig. 6B). Finally, we also examined the activation of

a DR1-ΔMTV-CAT reporter. This DR1 (AGGTCA n AGGTCA) sequence is thought to be a

specific response element for RXR (Kurokawa et al. 1994; Mangelsdorf, et al. 1995). Although

we found that this DR1 is a weaker response element than the IR sequence, co-transfection of an

RXR expression vector leads to ligand-induced activation of this DR1 reporter, which is also

further enhanced by NRIF3 (Fig. 6C).

NRIF3 does not potentiate the activity of GR, PR, ER, and VDR in vivo

The selective co-activation of TR and RXR (but not RAR) by NRIF3 is consistent with its distinct

binding specificity to these receptors. To further establish that NRIF3 acts as a receptor-specific

co-activator, we next examined the effect of NRIF3 on the activity of four additional nuclear

receptors, including GR, PR, ER, and VDR, by transfection studies. HeLa cells were transfected

with a GRE / PRE-tk-CAT reporter along with a vector expressing either GR or PR. As shown in

Figure 7A, cognate hormone treatment results in activation of the CAT reporter. However,

expression of NRIF3 has little effect (Fig. 7A). Similar experiments were carried out using ER

and ERE-ΔMTV-CAT, or VDR and VDRE-ΔMTV-CAT. As shown in Figure 7B and 7C, NRIF3

24

was found to have little or no effect on the activity of these receptors as well. Taken together, the combined results of our transfection studies support the notion that NRIF3 is a co-activator with a unique receptor specificity.

A novel C-terminal domain in NRIF3 is essential for ligand-dependent interactions with TR and RXR

The LxxLL signature motif has been found to be present in the receptor interacting domain of many identified co-activators such as SRC-1/NCoA-1 and GRIP1/TIF-2 (Heery, et al. 1997). The broad spectrum of receptor binding by co-activators such as SRC-1 suggests that the LxxLL-containing interacting domain may recognize a structurally-similar surface of these LBDs. Indeed, recent structural and functional studies revealed that the LxxLL motif and its nearby flanking amino acids are involved in direct contact with a hydrophobic cleft of the target surface presented by the ligand-bound LBDs of nuclear receptors (Darimont, et al. 1998; Feng, et al. 1998; McInerney, et al. 1998; Nolte, et al. 1998). The fact that NRIF3 also contains an LxxLL motif (amino acids 9-13, see Fig. 2 and Fig. 8A) and exhibits a distinct receptor specificity, raises the possibility that: 1), the motif and surrounding amino acids are involved in mediating the specificity found with NRIF3; or, 2) another region of NRIF3 (alone or in concert with the LxxLL motif region) plays an important role in mediating its receptor specificity.

To explore these questions, we examined whether the endonexin short form (EnS) and endonexin long form (EnL), which contain the same LxxLL motif and flanking amino acids as NRIF3, can interact with nuclear receptors in a yeast two-hybrid assay (Fig. 8). EnS consists of 111 amino acids and is 100% identical to the first 111 residues of NRIF3, while the first 161 amino acids of EnL (170 amino acids) is also 100% identical to the same region in NRIF3 (see Fig. 2 legend and Fig. 8A). Thus, NRIF3 and EnL differ only in their C-terminus, with a unique region of 16 amino acids in NRIF3 or 9 residues in EnL (Fig. 8A). Interestingly, despite their extensive identity with NRIF3, the interaction with liganded TR or RXR is completely abolished in EnS and EnL (Fig. 8B). We also examined other nuclear receptors that do not interact with

NRIF3 and found that they also do not interact with EnS or EnL (data not shown). These results indicate that the unique C-terminal domain in NRIF3 (residues 162-177) is essential for its specific interaction with liganded TR and RXR, while the N-terminal LxxLL motif (amino acids 9-13) and its flanking sequences are not sufficient to allow for detectable receptor interactions.

Although found to be not sufficient for interaction, we examined whether the LxxLL motif of NRIF3 contributes in the NRIF3 / receptor interaction by mutating the first leucine of the LxxLL motif into alanine (L9A) by site-directed mutagenesis. Previous studies have shown that the three leucine residues are essential for an LxxLL module to interact with receptor LBDs, and the replacement of any of them with alanine would abolish the interaction (Heery, et al. 1997). We examined the mutant NRIF3(L9A) for its interaction with TR and RXR in a yeast two-hybrid assay. As shown in Figure 9, the L9A mutant is still capable of ligand-dependent interaction with TR and RXR (~25-fold induction by ligand). However, the introduced mutation reduces the interaction by about 4-fold (for TR) or 14-fold (for RXR). These results suggest that although the LxxLL motif is not absolutely essential for NRIF3 interaction with liganded receptors, it plays a role in allowing an optimum interaction to occur.

An LxxIL-containing module within the C-terminal domain of NRIF3 appears to specifically interact with ligand-bound TR and RXR but not RAR

Secondary structure analysis of the C-terminal domain of NRIF3 predicts the formation of an α-helix. Inspection of the putative C-terminal helix revealed an LxxIL motif (amino acids 172-176). A previous study on the second LxxLL box of GRIP1 shows that substitution of the second leucine of the LxxLL core with phenylalanine reduces its affinity for liganded TR by about 50 to 100-fold (Darimont, et al. 1998). In addition, it has been suggested that the second and third (xx) amino acids of the LxxLL core play little if any role in the specificity of interaction with nuclear receptors (McInerney, et al. 1998). To clarify a role for the LxxIL- containing C-terminal helix of NRIF3 in receptor interactions, we modeled the docking of the NRIF3 C-terminal peptide with the ligand-bound LBDs of TRα, RXRα, and RARα. The background information and procedures

26

used for constructing these models are described in Materials and methods and the results are presented in Figure 10. Our models suggest that the substitution of the second leucine in an LxxLL core with isoleucine still permits a strong hydrophobic interaction with the liganded receptor (Table 2) while a lysine within the LxxIL motif of NRIF3 (K173) and an upstream arginine (R164) contribute to the specificity of NRIF3 binding to TR or RXR through electrostatic interactions. Figure 10 illustrates that the two leucines and one isoleucine (green and cyan) of the LxxIL motif are predicted to be deeply buried into the central cavity of the hydrophobic groove formed by the liganded LBDs of these receptors. In the modeled NRIF3 / RXR and NRIF3 / TR complexes, two specific electrostatic contacts are predicted to further stabilize the interaction: a lysine within the LxxIL motif itself (K173) contacts an acidic residue of the receptor (D295 for RXR or E241 for TR), and an arginine upstream of the LxxIL motif (R164) contacts glutamate(s) of the receptor (E453 for RXR or E399 and E402 for TR). In contrast, no such specific interaction is observed in the modeled NRIF3 / RAR complex.

Based on these models, a prediction of the binding energy between the 17-residue C-terminal peptide of NRIF3 and the LBDs of RXRα, TRα, or RARα was carried out (Table 2), using an improved partitioning binding energy function, with continuum representation of the electrostatics of the system (Schapira et al. 1999). The binding energy was calculated as the sum of a surface, or shape-complementarity term, an electrostatic term, and an entropic term (a constant which accounts for dilution effects and loss of rotational / translational degrees of freedom upon complexation, generally set between +7 and +15 kcal/mol, was omitted since we are more interested in the binding energy difference between the 3 complexes). Table 2 shows that the calculated binding energies for NRIF3 / RXR and NRIF3 / TR are very similar (~ -21 kcal/mol). In contrast, the binding energy is more than 20 kcal/mol less favorable for the NRIF3 / RAR complex. This difference comes mainly from the electrostatic term (Table 2). In the NRIF3 / RAR complex, the electrostatic desolvation penalty upon complexation is not counterbalanced by stabilizing specific coulombic interactions, as in the NRIF3 / RXR and NRIF3 / TR complexes. As a result, the electrostatic contribution to the binding energy is much more unfavorable for the

27

binding of NRIF3 to RAR than to RXR or TR. In summary, the large difference in the total binding energy between NRIF3 / RXR (or TR) and NRIF3 / RAR provides an explanation for the experimentally observed specificity of interaction of NRIF3 with these receptors.

As a control, we carried out a similar modeling procedure using the second LxxLL box within the receptor interacting domain of SRC-1. This LxxLL box has been shown to be required for interaction with TR (McInerney, et al. 1998). A 20-residue helix encompassing this LxxLL box (see Materials and methods) was docked to the co-activator binding site of the TRα LBD, and the binding energy was calculated (Table 2). Interestingly, the surface term of the SRC-1 / TR complex (-42 kcal/mol) was found to be close to the one determined for the NRIF3 / TR complex (-46.5 kcal/mol). This result suggests that the shape complementarity between NRIF3 and TR is comparable to that of SRC-1 / TR. The SRC-1 / TR complex is predicted to be stabilized by a specific interaction between an arginine that is four residues upstream of the LxxLL core, and two glutamates (E399 and E402) of the receptor, which mimics the contact made by R164 of NRIF3 shown in Figure 10. It is interesting to note that a basic residue at this position (i.e. four residues upstream of the LxxLL core) is conserved among the second LxxLL boxes of GRIP1, p/CIP and SRC-1 (Darimont, et al. 1998). Overall, the electrostatic term for SRC-1 / TR (11.3 kcal/mol) is close to the one determined for the NRIF3 / TR complex (12.4 kcal/mol). The total binding energies are also very similar (less than 3 kcal/mol apart, see Table 2).

Altogether, these models and calculations strongly suggest that NRIF3 binds to the co-activator binding site in the LBDs of TR and RXR through its C-terminal helix, where an LxxIL-containing module mimics the LxxLL-containing boxes of SRC-1 and GRIP1. Moreover, the receptor specificity of NRIF3 seems to result from a set of specific electrostatic interactions that involve basic residues both within the LxxIL itself (K173) and from its upstream sequence (R164). The presence (as for TR or RXR) or absence (as for RAR) of such electrostatic interactions likely plays a major role in determining the receptor specificity of NRIF3 that was observed experimentally.

Discussion

Recent efforts in understanding receptor-mediated transcription have led to the identification of a number of co-activators for nuclear hormone receptors, which can be categorized into two main groups based on overall homology, the SRC-1 family (including SRC-1/NCoA-1, TIF2/GRIP1/NCoA-2, AIB1/p/CIP/ACTR/RAC3/TRAM-1) (Onate, et al. 1995; Hong, et al. 1996; Kamei, et al. 1996; Voegel, et al. 1996; Anzick, et al. 1997; Chen, et al. 1997; Hong, et al. 1997; Li, et al. 1997; Takeshita, et al. 1997; Torchia, et al. 1997), and the CBP/p300 family (Chakravarti, et al. 1996; Hanstein, et al. 1996; Kamei, et al. 1996). Other putative co-activators (e.g. ARA70 and PGC-1) that do not belong to the SRC-1 or CBP/p300 families have also been identified (Yeh and Chang 1996; Puigserver, et al. 1998). In addition, p/CAF may also be involved in receptor action through its association with nuclear receptors as well as with other co-activators (Yang et al. 1996; Chen, et al. 1997; Blanco et al. 1998; Korzus et al. 1998). Among these known co-activators, CBP/p300, members of the SRC-1 group, and p/CAF all possess HAT activities (Bannister and Kouzarides 1996; Ogryzko, et al. 1996; Yang, et al. 1996; Chen, et al. 1997; Spencer, et al. 1997).

In this study we report the identification of a novel nuclear protein (NRIF3) which exhibits specific ligand-dependent interactions with TR and RXR but not with RAR, VDR, GR, PR, and ER. Functional studies indicate that NRIF3 potentiates TR- and RXR-mediated transactivation *in vivo* while it exhibits little or no effect on the activity of other examined receptors. Therefore, NRIF3 represents a novel co-activator with a distinct receptor specificity and, thus, may shed light on clarifying the molecular mechanism(s) underlying receptor-specific regulation of gene expression.

A database search indicated that NRIF3 shares no homology with any known co-activators except for a single LxxLL motif. An unusual feature of NRIF3 is its relatively small size, which is in sharp contrast to SRC-1 or CBP/p300. A homology search identified two alternatively spliced isoforms of NRIF3 which were previously designated as β3-endonexin short and long forms (Shattil, et al. 1995). Preliminary studies with these two endonexins indicate that, like NRIF3,

29

they also localize to the cell nucleus (S. Shattil, personnel communication; Li and Samuels, unpublished data). Interestingly, despite their extensive identities with NRIF3, both the endonexin short and long forms fail to exhibit interaction with liganded nuclear receptors (see Fig. 8). Consistent with this finding, we found that the endonexin short and long forms have little effect on receptor-mediated transcription in transfection studies (data not shown). Therefore, the precise roles of these two endonexins remain to be elucidated. We suggest two not mutually-excluding possibilities. First, since both the endonexin long and short forms appear to localize to the nucleus, it is possible that they may act as co-factors for other transcriptional regulators. Second, since the endonexin short form can interact with the cytoplasmic tail of β3-integrin (Shattil, et al. 1995; Eigenthaler et al. 1997), it may function to communicate signals generated at the plasma membrane to the cell nucleus. An example of a protein which is involved in both cell adhesion and transcriptional regulation is β-catenin (for a review, see Willert and Nusse 1998).

Previous study of the endonexins identified the presence of NRIF3-related mRNAs (by Northern blots) in a wide range of human tissues (Shattil, et al. 1995). Because NRIF3 and the endonexin long form contain almost identical nucleotide sequences and differ only by an alternative splice which results in the removal of a small exon in NRIF3, it is difficult to specifically identify NRIF3 mRNA by Northern blots. A search of the expressed sequence tag database indicates that NRIF3 as well as both the endonexin long and short form mRNAs are expressed. However, the precise determination of cell and tissue distribution of the individual NRIF3 and endonexin short and long forms will require the development of highly selective antibodies. Nevertheless, the wide expression pattern of NRIF3-related mRNAs is consistent with the role of NRIF3 as a co-activator of the TRs, which are also widely expressed (Strait et al. 1990), or the RXRs, which are ubiquitously expressed (Mangelsdorf et al. 1992).

A key question concerning the action of nuclear hormone receptors is to elucidate the molecular events underlying the functional specificity of different receptors in regulating the expression of their target genes. Determinants of specificity include specific ligand binding, selective binding of the receptors to their cognate response elements, as well as specific expression

30

pattern of different receptors. These determinants alone, however, are not always sufficient to explain the extent of specificity observed for members of the nuclear receptor family. For example, several members of the thyroid hormone / retinoid receptor subfamily may bind similarly to common DNA elements while target genes containing those elements are only selectively activated by certain receptors (Desai-Yajnik and Samuels 1993; MacDonald, et al. 1993). Therefore, it is likely that additional factors (determined by cell / promoter contexts) are involved in determining receptor functional specificity. In this respect, most known co-activators do not appear to be receptor-specific. For example, members of the SRC-1 family and CBP/p300 interact with and appear to be involved in the action of many nuclear receptors (Chakravarti, et al. 1996; Kamei, et al. 1996; Chen, et al. 1997; Hong, et al. 1997). Two known co-activators that may be involved in receptor-specific functions are ARA70 and PGC-1. The androgen receptor co-activator ARA70 has been reported to potentiate the activity of AR more efficiently than for other nuclear receptors (Yeh and Chang 1996). However, whether ARA70 can associate with other receptors remains to be thoroughly examined. The expression of PGC-1 is mainly restricted to the brown fat tissue and is thought to be directly involved in the regulation of thermogenesis by PPARγ (Puigserver, et al. 1998). Nevertheless, PGC-1 exhibits a relatively broad spectrum of binding to different nuclear receptors. Therefore, the identification of NRIF3 represents the first example of a co-activator with such a clearly-defined receptor specificity.

The receptor-specificity of NRIF3 raises an interesting question about its molecular mechanism. Domain analysis suggests that the LxxLL motif (amino acids 9-13) and its flanking sequences in NRIF3 are not sufficient for interaction with liganded nuclear receptors. In fact, such interaction is completely abolished in the endonexin long form, an alternatively spliced product which has the same LxxLL motif and contains the first 161 amino acids (out of a total of 177 amino acids) of NRIF3. This result suggests that a putative domain consisting of the last 16 amino acids of NRIF3 (residues 162-177) is essential for its interaction with liganded receptors. Inspection of this C-terminal region of NRIF3 indicates that it contains an LxxIL motif (amino acids 172-176) and secondary structure analysis predicts the formation of an α-helix. The

31

predicted helix structure and the similarity of LxxIL to the canonical LxxLL raise the possibility that this LxxIL-containing region may play a direct role in the specific interaction of NRIF3 with ligand-bound TR or RXR.

Modeling of the docking of a C-terminal peptide of NRIF3 containing the LxxIL motif to various ligand-bound LBDs (Fig. 10) and calculation of the resulting binding energies (Table 2) reveal several important points. First, the same hydrophobic groove in the ligand-bound LBD, which has been shown by previous studies to be the binding site for co-activators such as SRC-1/NCoA-1 or GRIP1 (Darimont, et al. 1998; Feng, et al. 1998; Nolte, et al. 1998), appears also to be a suitable site for the docking of the C-terminal helix of NRIF3. Thus, the utilization of the complementary pair of an α-helix (in the co-activator) and a hydrophobic groove (in the receptor) for interaction seems to be a general scheme that also applies to NRIF3. Second, the binding energy estimated for the NRIF3 peptide and the TR LBD (or RXR LBD) is similar to the one calculated for the second LxxLL box of SRC-1/NCoA-1 and the TR LBD. Third, the receptor specificity of the NRIF3 peptide appears to be determined by electrostatic interactions formed by K173 and R164 of the NRIF3 peptide with specific acidic residues of the ligand-bound LBDs of TR and RXR. Such charge interactions do not appear to occur in the similarly modeled ligand-bound LBD of RAR. This results in a predicted ~20 kcal/mol difference in the binding energy between NRIF3 / TR (or RXR) and NRIF3 / RAR, which would explain the differential interaction patterns of NRIF3 with these receptors. In summary, the C-terminal region of NRIF3 is predicted to directly contact the hydrophobic groove of liganded TR and RXR with high affinity, where specific basic amino acids upstream of and contained within the LxxIL motif play an important role in determining the binding affinity and / or specificity. While the models presented in Figure 10 need to be tested by more systematic mutagenesis studies in the future, we have examined two TR AF-2 mutants (Selmi-Ruby, et al. 1998) and found that in both cases, ligand-dependent interaction with NRIF3 was abolished (Li and Samuels, unpublished data). This result supports the notion that the integrity of the hydrophobic groove (in which the AF-2 helix of the receptor is an important constituent) is essential for NRIF3 binding, which is predicted by our models.

32

Although the N-terminal LxxLL motif (amino acids 9-13) is insufficient alone to mediate an interaction with TR or RXR (see Fig. 8), it can influence the interaction of NRIF3 with these receptors, as the NRIF3 L9A mutant retains significant but nevertheless reduced association with liganded TR or RXR (Fig. 9). Thus, NRIF3 appears to employ at least two regions in interacting with liganded TR or RXR, with the C-terminal helix playing an essential role and the N-terminal LxxLL motif playing a secondary role. A simplified explanation for these findings would be that the C-terminal helix of NRIF3 provides a major surface for receptor binding, and is responsible for most if not all of the receptor specificity of NRIF3, while the N-terminal LxxLL motif makes some minor contact with either the same receptor molecule, or more likely, with the other partner of a homodimer or heterodimer to further stabilize the NRIF3-receptor interaction. An example of a co-activator molecule employing two separate regions to interact with the two partners of a receptor dimer has been documented in the recently solved crystal structure of liganded PPARγ complexed with SRC-1/NCoA-1 (Nolte, et al. 1998). Without the C-terminal domain of NRIF3, the affinity of the N-terminal LxxLL motif alone with liganded TR or RXR is insufficient for receptor interaction. In summary, our results suggest that novel surfaces are involved in NRIF3 / receptor interaction and in determining receptor specificity of NRIF3. It is tempting to speculate that the employment of a core motif that is a variant of the canonical LxxLL (such as LxxIL) and the utilization of specific residues contained within and surrounding the core motif in determining receptor specificity could be a strategy that not only applies to NRIF3, but also to other yet to be defined receptor interacting factors as well.

Accumulating evidence suggests that the actions of transcriptional activating proteins are (usually) mediated by multi-protein complexes (for a review, see Orphanides et al. 1996) and such a scheme is also likely for nuclear receptors. For example, biochemical evidence suggests that multi-protein complexes associate with liganded TR and VDR (Fondell et al. 1996; Rachez et al. 1998; Yuan et al. 1998). Interestingly, many of the proteins identified in these studies are not known co-activators. While the study of known co-activators such as CBP/p300 and the SRC-1 family has suggested that histone acetylation may play an important role in receptor-mediated

33

transactivation (Bannister and Kouzarides 1996; Ogryzko, et al. 1996; Chen, et al. 1997; Spencer, et al. 1997), detailed elucidation of the transactivation mechanism(s) by these receptors awaits the identification and study of additional co-factors involved in the transactivation process.

Our results with NRIF3 suggest that transcriptional activation by nuclear receptors may employ receptor-specific co-activator(s) in addition to the generally-utilized co-activators such as CBP or SRC-1. Therefore, co-activators with NRIF3-like properties may contribute to the functional specificity of nuclear receptors *in vivo*. Based on our results with NRIF3 and previous studies of nuclear receptor action, we suggest a "combinatorial specificity model" where a co-activation complex is likely composed of two kinds of factors: "general factors" that interact with and are involved in the action of many nuclear receptors (such as CBP or SRC-1), and "specific factors" that exhibit receptor specificity (such as NRIF3). In addition to their interaction with the liganded receptor, co-activators may also communicate with each other within the co-activation complex through protein-protein interactions (e.g. CBP/p300 can interact with SRC-1/NCoA-1 or p/CIP) (Kamei, et al. 1996; Yao et al. 1996; Torchia, et al. 1997). The combinatorial actions of "specific factors" and other partners involved in the transactivation process may facilitate the recruitment of specific co-activation complexes for different receptors (under different cell / promoter / HRE contexts), which would provide an important mechanistic layer for receptor functional specificity. An advantage of employing such a combinatorial strategy is that a broad array of diversity can be generated from a relatively small number of involved factors. Further study of NRIF3 with known and possibly other yet to be identified co-activators, as well as analysis of the interplay among these co-activators should provide important insights into the molecular mechanism(s) underlying the specificity of receptor-mediated regulation of target gene expression.

Materials and methods

Isolation of NRIFs and the yeast two-hybrid assay

The Brent two-hybrid system (Gyuris, et al. 1993) was employed to isolate candidate cDNA clones interacting with LexA-TRα in a ligand-dependent fashion. Full length chicken TRα (cTRα) was fused in frame to the C-terminus of the LexA DBD in pEG202 (Gyuris, et al. 1993). The LexA-TRα bait, the LacZ reporter (pSH18-34), and a pJG4-5 based HeLa cell cDNA library were transformed into the yeast strain EGY48 (Gyuris, et al. 1993). The transformants were selected on Gal/Raf/X-gal medium in the absence of leucine and were further screened for the expression of LacZ in the presence of 1μM T3. Blue colonies were picked and re-examined for T3-dependent expression of LacZ. Positive yeast clones were then selected and plasmids harboring candidate prey cDNAs were isolated. Individual candidate prey plasmid was then amplified in E. coli and re-transformed into the original yeast strain to confirm the interaction phenotype. The cDNA inserts were then sequenced using an automatic sequencer. Four novel clones (NRIF1, 2, 3, and 4) were obtained. Among them, NRIF3 was a full length clone.

Wild type NRIF3, the endonexin long form (EnL) and short form (EnS), and the L9A NRIF3 mutant were examined for their interaction with various nuclear receptors in a yeast two-hybrid assay. The following receptor baits were used: LexA-cTRα LBD, LexA-hTRβ LBD, LexA-hRARα LBD, LexA-hRXRα LBD, and LexA-hGR LBD. Yeast cells harboring appropriate plasmids were grown in selective media with Gal/Raf in the presence or absence of cognate ligand (1 μM T3 for TR, all trans or 9-cis RA for RAR, 9-cis RA for RXR, and 10 μM deoxycorticosterone for GR) overnight before β-galactosidase activity was assayed using o-Nitrophenyl β-D-Galactopyranoside as the substrate. β-galactosidase units are expressed as (O.D. 420 nm x 1000) / (minutes of incubation x O.D. 600 nm of yeast suspension).

Fluorescence Microscopy

Full length NRIF3 was cloned into the GFP fusion protein expression vector pEGFP (Clontech). The resulting GFP-NRIF3 vector and the control plasmid pEGFP were transfected into HeLa cells

by calcium phosphate co-precipitation. Cells were incubated at 37°C for 24 hours before the examination with a fluorescence microscope to determine the subcellular location of GFP-NRIF3 or the GFP control.

In vitro binding assay

Full length NRIF3 was cloned into pGEX2T, a bacterial GST-fusion protein expression vector (Pharmacia). The GST-NRIF3 fusion protein was expressed in E. coli and affinity purified using glutathione-agarose beads (Hadzic, et al. 1995). ^{35}S-labeled full length cTRα, hRARα, hRXRα hVDR, hGR, hPR, and hER were generated by *in vitro* transcription / translation using a reticulocyte lysate system (Promega). Binding was performed as previously described (Hadzic, et al. 1995), using the following buffer: 20 mM Hepes (pH 7.9), 1 mM $MgCl_2$, 1 mM DTT, 10% Glycerol, 0.05% Triton X-100, 1 μM $ZnCl_2$, and 150 mM KCl. Appropriate ligands were added into the binding reaction when indicated: 1 μM T3 for TR, 1 μM all trans RA or 9-cis RA for RAR, 1 μM 9-cis RA for RXR, and 150 nM 1,25-$(OH)_2$ VitD3, dexamethathone, progesterone, or estradiol for VDR, GR, PR, or ER. After the binding reaction, the beads were washed three times and the labeled receptors bound to the beads were examined in 10% SDS-PAGE followed by autoradiography. Five percent of the ^{35}S-labeled receptor input was also electrophoresed in the same gel.

Transfection studies

Most reporters used in this study have been described previously, including IR-ΔMTV-CAT, DR4-ΔMTV-CAT, GH-TRE-tk-CAT, IR+3 (ERE)-ΔMTV-CAT (Umesono, et al. 1991; Forman, et al. 1992; Au-Fliegner, et al. 1993). A DR1-ΔMTV-CAT reporter responsive to RXR was obtained from Ron Evans. A GRE / PRE-tk-CAT reporter was obtained from Gunther Schutz. The (IR)2-TATA-CAT was constructed in our laboratory by cloning two copies of the IR sequence (AGGTCA TGACCT) upstream of a TATA element derived from the tk promoter. A hVDR expression vector and the VDRE-ΔMTV-CAT containing the VDRE from the osteocalcin promoter

were obtained from J. Wesley Pike. Vectors expressing cTRα, hRARα, hRXRα, rGR, hPR, and

hER have been described previously (Conneely et al. 1986; Miesfeld et al. 1986; Giguere et al.

1987; Waterman et al. 1988; Mangelsdorf et al. 1990; Forman, et al. 1992). The NRIF3

expression vector was constructed by cloning full length NRIF3 into a pExpress vector (Forman,

et al. 1992). Appropriate plasmids were transfected into HeLa cells by calcium phosphate co-

precipitation using 25-100 ng of the receptors, 250-500 ng of the CAT reporters, and 750 ng of the

NRIF3 or control pExpress vector. After transfection, cells were incubated at 37°C (with or

without cognate ligands) for 42 hours before being harvested. CAT assays were carried out as

previously described (Hadzic, et al. 1995). Relative CAT activity was determined as the percent

acetylation of substrate per 30 μg of cell protein in a 15 hour incubation at 37°C. The results were

calculated from duplicate or quadruplicate samples and the variation among samples was less than

10%.

Domain and mutagenesis analyses

To construct pJG4-5 derived vectors expressing EnL or EnS, the pJG4-5/NRIF3 plasmid was

digested with NcoI and XhoI, and the resulting vector fragment was gel-purified. This fragment

was then ligated to an EnL or EnS insert generated from pExpress-EnL or pExpress-EnS by an

NcoI / SalI double digest. The resulting pJG4-5/EnL or EnS plasmids were confirmed by

sequence analysis. The L9A mutant form of NRIF3 was generated by site-directed mutagenesis

using a PCR-based method, and the mutation was confirmed by sequence analysis. pJG4-5

derived vectors expressing EnL, EnS, or the L9A NRIF3 mutant form were transformed into yeast

strains harboring the LacZ reporter (pSH18-34) and appropriate bait plasmids (LexA-TR, LexA-

RAR, LexA-RXR, and LexA-GR). Transformants were subjected to quantitative assays of β-

galactosidase activity as described earlier.

Docking of co-activator peptides to receptors

We built a model of the interaction between the 17-residue C-terminal peptide of NRIF3 (KASRHLDSYEFLKAILN) and the LBDs of RXRα, TRα or RARα. An LxxIL motif within the NRIF3 peptide is underlined. A similar modeling procedure was carried out on a 20-residue peptide (SLTERHKILHRLLQEGSPSD) of the second LxxLL box of SRC-1 (McInerney, et al. 1998). The crystal structures of ligand-bound TRα (Wagner et al. 1995) and RARγ (Renaud et al. 1995). were used, while the conformation of liganded RXRα was modeled from its inactive state (see below). We hypothesized that the LxxIL motif of the C-terminus of NRIF3 contacts the co-activator binding site of the nuclear receptors, and the automatic docking procedure was carried out towards this site (Totrov and Abagyan 1994; Strynadka et al. 1996; Totrov and Abagyan 1997). Two critical features of the interaction between the LBDs of nuclear hormone receptors and their co-activators were used to build the models: 1) The "charge clamp", initially observed in the complex between SRC-1 and PPARγ (Nolte, et al. 1998), where a conserved glutamate and lysine at opposite ends of the hydrophobic cavity of the receptors contact the backbone of the co-activator's LxxLL box. This feature enabled the orientation of the NRIF3 helical peptide and, 2) The finding that the leucines of the LxxLL motif of SRC-1 are buried into the hydrophobic cavity of the receptor. This feature makes predictions of the side of the NRIF3 peptide which faces the receptor.

The co-activator peptides were assigned a helical secondary structure, the backbone ϕ and ψ angles being -62 and -41 degrees, respectively. The ω angle was set to 180 degrees. Loose distance restraints were set between the "charge clamp" of the receptors (Nolte, et al. 1998) and C^α atoms of the peptide. The energy of the complex was minimized in the internal coordinate space using the modified ECEPP/3 potentials. The subset of the variables minimized with the ICM method (Abagyan et al. 1994; Strynadka, et al. 1996; Totrov and Abagyan 1997), included the side-chains of the receptor, six positional variables of the helix and the side-chain torsion angles of the helix.

Modeling of the conformation of ligand-bound RXRα and RARα

9-cis RA was docked into the crystal structure of the binding pocket of RARγ with the flexible docking procedure. First, the continuously flexible ligand was docked into a set of five grid potentials (small probe van der Waals grid, large probe van der Waals grid, electrostatic potential, hydrogen bonding potential and the hydrophobic potential). Second, the ligand was refined together with the flexible receptor side-chains (Totrov and Abagyan 1997). The model of the RXRα / 9-cis RA complex was derived from the RARγ / 9-cis RA complex by replacement of the side-chains, followed by the energy optimization.

In order to analyze the co-activator helix binding of RARα, we built a model of RARα LBD based on the close homology to the known RARγ isoform. The two isoforms share 80% sequence identify. The four residues non-identical between the two isoforms, which are in the vicinity of the co-activator binding pocket were changed to the RARα isoform type (R247Q, P407S, R413Q, P419S), and the energy was minimized. Peptide docking results were found to be similar for RARα and RARγ

Binding energy calculation:

The binding energy was calculated by the partitioning method as described elsewhere (Schapira, et al. 1999). Briefly, the binding energy function is partitioned into three terms: the surface (or hydrophobic) term, determined as the product of the solvent accessible surface by a surface tension of 30 cal/mol/$Å^2$, the electrostatic term, calculated by a boundary element algorithm, with a dielectric constant of 8, and the entropic term, which results from the decrease in conformational freedom of residue side-chains partially or completely buried upon complexation.

Acknowledgments

References

Abagyan, R.A., M.M. Totrov, and D.A. Kuznetsov. 1994. ICM: a new method for structure modeling and design: Applications to docking and structure prediction from the distorted native conformation. *J. Comp. Chem.* **15:** 488-506.

Anzick, S.L., J. Kononen, R.L. Walker, D.O. Azorsa, M.M. Tanner, X.Y. Guan, G. Sauter, O.P. Kallioniemi, J.M. Trent, and P.S. Meltzer. 1997. AIB1, a steroid receptor coactivator amplified in breast and ovarian cancer. *Science* **277:** 965-968.

Arany, Z., D. Newsome, E. Oldread, D.M. Livingston, and R. Eckner. 1995. A family of transcriptional adaptor proteins targeted by the E1A oncoprotein. *Nature* **374:** 81-84.

Arias, J., A.S. Alberts, P. Brindle, F.X. Claret, T. Smeal, M. Karin, J. Feramisco, and M. Montminy. 1994. Activation of cAMP and mitogen responsive genes relies on a common nuclear factor. *Nature* **370:** 226-229.

Au-Fliegner, M., E. Helmer, J. Casanova, B.M. Raaka, and H.H. Samuels. 1993. The conserved ninth C-terminal heptad in thyroid hormone and retinoic acid receptors mediates diverse responses by affecting heterodimer but not homodimer formation. *Mol. Cell. Biol.* **13:** 5725-5737.

Baniahmad, A., X. Leng, T.P. Burris, S.Y. Tsai, M.-J. Tsai, and B.W. O'Malley. 1995. The τ4 activation domain of the thyroid hormone receptor is required for release of a putative corepressor(s) necessary for transcriptional silencing. *Mol. Cell. Biol.* **15:** 76-86.

Bannister, A.J. and T. Kouzarides. 1995. CBP-induced stimulation of c-Fos activity is abrogated by E1A. *EMBO J.* **14:** 4758-4762.

41

Bannister, A.J. and T. Kouzarides. 1996. The CBP co-activator is a histone acetyltransferase. *Nature* **384:** 641-643.

Barettino, D., M.d.M.V. Ruiz, and H.G. Stunnenberg. 1994. Characterization of the ligand-dependent transactivation domain of thyroid hormone receptor. *EMBO J.* **13:** 3039-3049.

Bhattacharya, S., R. Eckner, S. Grossman, E. Oldread, Z. Arany, A. D'Andrea, and D.M. Livingston. 1996. Cooperation of Stat2 and p300/CBP in signalling induced by interferon-alpha. *Nature* **383:** 344-347.

Blanco, J.C.G., S. Minucci, J. Lu, X.J. Yang, K.K. Walker, H. Chen, R.M. Evans, V. Nakatani, and K. Ozato. 1998. The histone acetylase PCAF is a nuclear receptor coactivator. *Genes Dev.* **12:** 1638-1651.

Casanova, J., E. Helmer, S. Selmi-Ruby, J.-S. Qi, M. Au-Fliegner, V. Desai-Yajnik, N. Koudinova, F. Yarm, B.M. Raaka, and H.H. Samuels. 1994. Functional evidence for ligand-dependent dissociation of thyroid hormone and retinoic acid receptors from an inhibitory cellular factor. *Mol. Cell. Biol.* **14:** 5756-5765.

Chakravarti, D., V.J. LaMorte, M.C. Nelson, T. Nakajima, I.G. Schulman, H. Juguilon, M. Montminy, and R.M. Evans. 1996. Role of CBP/P300 in nuclear receptor signalling. *Nature* **383:** 99-103.

Chen, H., R.J. Lin, R.L. Schiltz, D. Chakravarti, A. Nash, L. Nagy, M.L. Privalsky, Y. Nakatani, and R.M. Evans. 1997. Nuclear receptor coactivator ACTR is a novel histone acetyltransferase and forms a multimeric activation complex with P/CAF and CBP/p300. *Cell* **90:** 569-580.

Chen, J.D. and R.M. Evans. 1995. A transcriptional co-repressor that interacts with nuclear hormone receptors. *Nature* **377:** 454-457.

Chrivia, J.C., R.P. Kwok, N. Lamb, M. Hagiwara, M.R. Montminy, and R.H. Goodman. 1993. Phosphorylated CREB binds specifically to the nuclear protein CBP. *Nature* **365:** 855-859.

Conneely, O.M., W.P. Sullivan, D.O. Toft, M. Birnbaumer, R.G. Cook, B.L. Maxwell, T. Zaraucko-Schulz, G.L. Greene, W.T. Schraeder, and B.W. O'Malley. 1986. Molecular cloning of the chicken progesterone receptor. *Science* **233:** 767-770.

Cormack, B.P., R.H. Valdivia, and S. Falkow. 1996. FACS-optimized mutants of the green fluorescent protein (GFP). *Gene* **173:** 33-38.

Darimont, B.D., R.L. Wagner, J.W. Apriletti, M.R. Stallcup, P.J. Kushner, D. Baxter, R.J. Fletterick, and K.R. Yamamoto. 1998. Structure and specificity of nuclear receptor-coactivator interactions. *Genes Dev.* **12:** 3343-3356.

Desai-Yajnik, V. and H.H. Samuels. 1993. The NF-κB and Sp1 DNA motifs of the human immunodeficiency virus type 1 long terminal repeat function as novel thyroid hormone response elements. *Mol. Cell. Biol.* **13:** 5057-5069.

Durand, B., M. Saunders, C. Gausdon, B. Roy, R. Losson, and P. Chambon. 1994. Activation function 2 (AF-2) of retinoic acid receptor and 9-cis retinoic acid receptor: presence of a conserved autonomous constitutive activating domain and influence of the nature of the response element on AF-2 activity. *EMBO* **13:** 5370-5382.

Eigenthaler, M., L. Hofferer, S.J. Shattil, and M.H. Ginsberg. 1997. A conserved sequence motif in the integrin β3 cytoplasmic domain is required for its specific interaction with β3-endonexin. *J. Biol. Chem.* **272:** 7693-7698.

Feng, W., R.C. Ribeiro, R.L. Wagner, H. Nguyen, J.W. Apriletti, R.J. Fletterick, J.D. Baxter, P.J. Kushner, and B.L. West. 1998. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. *Science* **280:** 1747-1749.

Fondell, J.D., H. Ge, and R.G. Roeder. 1996. Ligand induction of a transcriptionally active thyroid hormone receptor coactivator complex. *Proc. Natl. Acad. Sci. USA* **93:** 8329-8333.

Forman, B.M., J. Casanova, B.M. Raaka, J. Ghysdael, and H.H. Samuels. 1992. Half-site spacing and orientation determines whether thyroid hormone and retinoic acid receptors and related factors bind to DNA response elements as monomers, homodimers, or heterodimers. *Mol. Endocrinol.* **6:** 429-442.

Giguere, V., E.S. Ong, P. Segui, and R.M. Evans. 1987. Identification of a receptor for the morphogen retinoic acid. *Nature* **330:** 624-629.

Glass, C.K., D.W. Rose, and M.G. Rosenfeld. 1997. Nuclear receptor coactivators. *Curr. Opin. Cell Biol.* **9:** 222-232.

Gu, W., X.L. Shi, and R.G. Roeder. 1997. Synergistic activation of transcription by CBP and p53. *Nature* **387:** 819-823.

Gyuris, J., E. Golemis, H. Chertkov, and R. Brent. 1993. Cdi1, a human G1 and S phase protein phosphatase that associates with Cdk2. *Cell* **75:** 791-803.

Hadzic, E., V. Desai-Yajnik, E. Helmer, S. Guo, S. Wu, N. Koudinova, J. Casanova, B.M. Raaka, and H.H. Samuels. 1995. A 10-amino-acid sequence in the N-terminal A/B domain of thyroid hormone receptor α is essential for transcriptional activation and interaction with the general transcription factor TFIIB. *Mol. Cell. Biol.* **15:** 4507-4517.

Hanstein, B., R. Eckner, J. DiRenzo, S. Halachmi, H. Liu, B. Searcy, R. Kurokawa, and M. Brown. 1996. p300 is a component of an estrogen receptor coactivator complex. *Proc. Natl. Acad. Sci. USA* **93:** 11540-11545.

Heery, D.M., E. Kalkhoven, S. Hoare, and M.G. Parker. 1997. A signature motif in transcriptional co-activators mediates binding to nuclear receptors. *Nature* **387:** 733-736.

Heinzel, T., R.M. Lavinsky, T.M. Mullen, M. Soderstrom, C.D. Laherty, J. Torchia, W.M. Yang, G. Brard, S.D. Ngo, J.R. Davie, E. Seto, R.N. Eisenman, D.W. Rose, C.K. Glass, and M.G. Rosenfeld. 1997. A complex containing N-CoR, mSin3 and histone deacetylase mediates transcriptional repression. *Nature* **387:** 43-48.

Hong, H., K. Kohli, M. Garabedian, and M.R. Stallcup. 1997. GRIP1, a transcriptional coactivator for the AF-2 transactivation domain of steroid, thyroid, retinoid, and vitamin D receptors. *Mol. Cell. Biol.* **17:** 2735-2744.

Hong, H., K. Kohli, A. Trivedi, D.L. Johnson, and M.R. Stallcup. 1996. GRIP1, a novel mouse protein that serves as a transcriptional coactivator in yeast for the hormone binding domains of steroid receptors. *Proc. Natl. Acad. Sci. USA* **93:** 4948-4952.

Horlein, A.J., A.M. Naar, T. Heinzel, J. Torchia, B. Gloss, R. Kurokawa, A. Ryan, Y. Kamil, M. Soderstrom, C.K. Glass, and M.G. Rosenfeld. 1995. Ligand-independent repression by the thyroid hormone receptor mediated by a nuclear receptor co-repressor. *Nature* **377**: 397-404.

Kamei, Y., L. Xu, T. Heinzel, J. Torchia, R. Kurokawa, B. Gloss, S.-C. Lin, R.A. Heyman, D.W. Rose, C.K. Glass, and M.G. Rosenfeld. 1996. A CBP integrator complex mediates transcriptional activation and AP-1 inhibition by nuclear receptors. *Cell* **85**: 403-414.

Korzus, E., J. Torchia, D.W. Rose, L. Xu, R. Kurokawa, E.M. McInerney, T.M. Mullen, C.K. Glass, and M.G. Rosenfeld. 1998. Transcription factor-specific requirements for coactivators and their acetyltransferase functions. *Science* **279**: 703-707.

Kurokawa, R., J. DiRenzo, M. Boehm, J. Sugarman, B. Gloss, M.G. Rosenfeld, R.A. Heyman, and C.K. Glass. 1994. Regulation of retinoid signalling by receptor polarity and allosteric control of ligand binding. *Nature* **371**: 528-531.

Kwok, R.P., J.R. Lundblad, J.C. Chrivia, J.P. Richards, H.P. Bachinger, R.G. Brennan, S.G. Roberts, M.R. Green, and R.H. Goodman. 1994. Nuclear protein CBP is a coactivator for the transcription factor CREB. *Nature* **370**: 223-226.

Lee, J.W., H.-S. Choi, J. Gyuris, R. Brent, and D.D. Moore. 1995. Two classes of proteins dependent on either the presence or absence of thyroid hormone for interaction with the thyroid hormone receptor. *Mol. Endocrinol.* **9**: 243-254.

Leng, X., J. Blanco, S.Y. Tsai, K. Ozato, B.W. O'Malley, and M.-J. Tsai. 1995. Mouse retinoid X receptor contains a separable ligand-binding and transactivation domain in its E region. *Mol. Cell. Biol.* **15**: 255-263.

Li, H., P.J. Gomes, and J.D. Chen. 1997. RAC3, a steroid/nuclear receptor-associated coactivator that is related to SRC-1 and TIF2. *Proc. Natl. Acad. Sci. USA* **94:** 8479-8484.

Lill, N.L., S.R. Grossman, D. Ginsberg, J. DeCaprio, and D.M. Livingston. 1997. Binding and modulation of p53 by p300/CBP coactivators. *Nature* **387:** 823-827.

Lundblad, J.R., R.P. Kwok, M.E. Laurance, M.L. Harter, and R.H. Goodman. 1995. Adenoviral E1A-associated protein p300 as a functional homologue of the transcriptional co-activator CBP. *Nature* **374:** 85-88.

MacDonald, P.N., D.R. Dowd, S. Nakajima, M.A. Galligan, M.C. Reeder, C.A. Haussler, K. Ozato, and M.R. Haussler. 1993. Retinoid X receptors stimulate and 9-cis retinoic acid inhibits 1,25-dihydroxyvitamin D_3-activated expression in the rat osteocalcin gene. *Mol. Cell. Biol.* **13:** 5907-5917.

Mangelsdorf, D.J., U. Borgmeyer, R.A. Heyman, J.Y. Zhou, E.S. Ong, A.E. Oro, A. Kakizuka, and R.M. Evans. 1992. Characterization of three RXR genes that mediate the action of *9-cis* retinoic acid. *Genes Dev.* **6:** 329-344.

Mangelsdorf, D.J. and R.M. Evans. 1995. The RXR heterodimers and orphan receptors. *Cell* **83:** 841-850.

Mangelsdorf, D.J., E.S. Ong, J.A. Dyck, and R.M. Evans. 1990. Nuclear receptor that identifies a novel retinoic acid response pathway. *Nature* **345:** 224-229.

Mangelsdorf, D.J., C. Thummel, M. Beato, P. Herrlich, G. Schutz, K. Umesono, B. Blumberg, P. Kastner, M. Mark, P. Chambon, and R.M. Evans. 1995. The nuclear receptor superfamily: the second decade. *Cell* **83:** 835-839.

McInerney, E.M., D.W. Rose, S.E. Flynn, S. Westin, T.M. Mullen, A. Krones, J. Inostroza, J. Torchia, R.T. Nolte, N. Assa-Munt, M.V. Milburn, C.K. Glass, and M.G. Rosenfeld. 1998. Determinants of coactivator LXXLL motif specificity in nuclear receptor transcriptional activation. *Genes Dev.* **12:** 3357-3368.

Miesfeld, R., S. Rusconi, P.J. Godowski, B.A. Maler, S. Okret, A.-C. Wikstrom, J.-A. Gustafsson, and K.R. Yamamoto. 1986. Genetic complementation of a glucocorticoid receptor deficiency by expression of cloned receptor cDNA. *Cell* **46:** 389-399.

Nagpal, S., S. Friant, H. Nakshatri, and P. Chambon. 1993. RARs and RXRs: evidence for two autonomous transactivation functions (AF-1 and AF-2) and heterodimerization *in vivo*. *EMBO J.* **12:** 2349-2360.

Nagy, L., H.V. Kao, D. Chakravarti, R.J. Lin, C.A. Hassig, D.E. Ayer, S.L. Schreiber, and R.M. Evans. 1997. Nuclear receptor repression mediated by a complex containing SMRT, mSin3A, and histone deacetylase. *Cell* **89:** 373-380.

Nolte, R.T., G.B. Wisely, S. Westin, J.E. Cobb, M.H. Lambert, R. Kurokawa, M.G. Rosenfeld, T.M. Willson, C.K. Glass, and M.V. Milburn. 1998. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-γ. *Nature* **395:** 137-143.

Ogryzko, V.V., R.L. Schiltz, V. Russanova, B.H. Howard, and Y. Nakatani. 1996. The transcriptional coactivators p300 and CBP are histone acetyltransferases. *Cell* **87:** 953-959.

Onate, S.A., S.Y. Tsai, M.-J. Tsai, and B.W. O'Malley. 1995. Sequence and characterization of a coactivator of the steroid hormone receptor superfamily. *Science* **270:** 1354-1357.

Orphanides, G., T. Lagrange, and D. Reinberg. 1996. The general transcription factors of RNA polymerase II. *Genes Dev.* **10:** 2657-2683.

Puigserver, P., Z. Wu, C.W. Park, R. Graves, M. Wright, and B.M. Spiegelman. 1998. A cold-inducible coactivator of nuclear receptors linked to adaptive thermogenesis. *Cell* **92:** 829-839.

Qi, J.-S., V. Desai-Yajnik, M.E. Greene, B.M. Raaka, and H.H. Samuels. 1995. The ligand binding domains of the thyroid hormone/retinoid receptor gene subfamily function *in vivo* to mediate heterodimerization, gene silencing, and transactivation. *Mol. Cell. Biol.* **15:** 1817-1825.

Rachez, C., Z. Suldan, J. Ward, C.P. Chang, D. Burakov, H. Erdjument-Bromage, P. Tempst, and L.P. Freedman. 1998. A novel protein complex that interacts with the vitamin D3 receptor in a ligand-dependent manner and enhances VDR transactivation in a cell-free system. *Genes Dev.* **12:** 1787-1800.

Renaud, J.-P., N. Rochel, M. Ruff, V. Vivat, P. Chambon, H. Gronemeyer, and D. Moras. 1995. Crystal structure of the RAR-γ ligand-binding domain bound to all-*trans* retinoic acid. *Nature* **378:** 681-689.

Schapira, M., M. Totrov, and R.A. Abagyan. 1999. Prediction of the binding energy for small molecules, peptides and proteins. *J. Mol. Recognit.* **12:** In press.

Schule, R., K. Umesono, D.J. Mangelsdorf, J. Bolado, J.W. Pike, and R.M. Evans. 1990. Jun-Fos and receptors for vitamins A and D recognize a common response element in the human osteocalcin gene. *Cell* **61:** 497-504.

Selmi-Ruby, S., J. Casanova, S. Malhotra, B. Roussett, B.M. Raaka, and H.H. Samuels. 1998. Role of the conserved C-terminal region of thyroid hormone receptor-α in ligand-dependent transcriptional activation. *Mol. Cell. Endo.* **138:** 105-114.

Shattil, S.J., T. O'Toole, M. Eigenthaler, V. Thon, M. Williams, B.M. Babior, and M.H. Ginsberg. 1995. β3-endonexin, a novel polypeptide that interacts specifically with the cytoplasmic tail of the integrin β3 subunit. *J. Cell Biol.* **131:** 807-816.

Sheikh, M.S., Z.-M. Shao, X.-S. Li, M. Dawson, A.M. Jetten, S. Wu, B.A. Conley, M. Garcia, H. Rochefort, and J.A. Fontana. 1994. Retinoid-resistant estrogen receptor-negative human breast carcinoma cells transfected with retinoic acid receptor-α acquire sensitivity to growth inhibition by retinoids. *J. Biol. Chem.* **269:** 21440-21447.

Spencer, T.E., G. Jenster, M.M. Burcin, C.D. Allis, J. Zhou, C.A. Mizzen, N.J. McKenna, S.A. Onate, S.Y. Tsai, M.J. Tsai, and B.W. O'Malley. 1997. Steroid receptor coactivator-1 is a histone acetyltransferase. *Nature* **389:** 194-198.

Strait, K., H.L. Schwartz, A. Perez-Castillo, and J.H. Oppenheimer. 1990. Relationship of c-erbA mRNA content to tissue triiodothyronine nuclear binding capacity and function in developing and adult rats. *J. Biol. Chem.* **265:** 10514-10521.

Strynadka, N.C., M. Eisenstein, E. Katchalski-Katzir, B.K. Shoichet, I.D. Kuntz, R. Abagyan, M. Totrov, J. Janin, J. Cherfils, F. Zimmerman, A. Olson, B. Duncan, M. Rao, R. Jackson, M.

Sternberg, and M.N. James. 1996. Molecular docking programs successfully predict the binding of a beta-lactamase inhibitory protein to TEM-1 beta-lactamase. *Nat. Struct. Biol.* **3:** 233-239.

Sugawara, A., N. Sanno, N. Takahashi, R.Y. Osamura, and K. Abe. 1997. Retinoid X receptors in the kidney: their protein expression and functional significance. *Endocrinology* **138:** 3175-3180.

Takeshita, A., G.R. Cardona, N. Koibuchi, C.S. Suen, and W.W. Chin. 1997. TRAM-1, A novel 160-kDa thyroid hormone receptor activator molecule, exhibits distinct properties from steroid receptor coactivator-1. *J. Biol. Chem.* **272:** 27629-27634.

Torchia, J., D.W. Rose, J. Inostroza, Y. Kamei, S. Westin, C.K. Glass, and M.G. Rosenfeld. 1997. The transcriptional co-activator p/CIP binds CBP and mediates nuclear-receptor function. *Nature* **387:** 677-684.

Totrov, M. and R. Abagyan. 1994. Detailed ab initio prediction of lysozyme-antibody complex with 1.6 A accuracy. *Nat. Struct. Biol.* **1:** 259-263.

Totrov, M. and R. Abagyan. 1997. Flexible protein-ligand docking by global energy optimization in internal coordinates. *Proteins* Suppl 1:215-220.

Umesono, K. and R.M. Evans. 1989. Determinants of target gene specificity for steroid/thyroid hormone receptors. *Cell* **57:** 1139-1146.

Umesono, K., K.K. Murakami, C.C. Thompson, and R.M. Evans. 1991. Direct repeats as selective response elements for the thyroid hormone, retinoic acid, and vitamin D receptors. *Cell* **65:** 1255-1266.

Voegel, J.J., M.J.S. Heine, C. Zechel, P. Chambon, and H. Gronemeyer. 1996. TIF2, a 160 kDa transcriptional mediator for the ligand-dependent activation function AF-2 of nuclear receptors. *EMBO J.* **15:** 3667-3675.

Wagner, R.L., J.W. Apriletti, M.E. McGrath, B.L. West, J.D. Baxter, and R.J. Fletterick. 1995. A structural role for hormone in the thyroid hormone receptor. *Nature* **378:** 690-697.

Waterman, M.L., S. Adler, C. Nelson, G.L. Greene, R.M. Evans, and M.G. Rosenfeld. 1988. A single domain of the estrogen receptor confers deoxyribonucleic acid binding and transcriptional activation of the rat prolactin gene. *Mol. Endocrinol.* **2:** 14-21.

Willert, K. and R. Nusse. 1998. Beta-catenin: a key mediator of Wnt signaling. *Curr Opin Genet Dev* **8:** 95-102.

Yang, X.J., V.V. Ogryzko, J. Nishikawa, B.H. Howard, and Y. Nakatani. 1996. A p300/CBP-associated factor that competes with the adenoviral oncoprotein E1A. *Nature* **382:** 319-324.

Yao, T.P., G. Ku, N. Zhou, R. Scully, and D.M. Livingston. 1996. The nuclear hormone receptor coactivator SRC-1 is a specific target of p300. *Proc. Natl. Acad. Sci. USA* **93:** 10626-10631.

Yeh, S. and C. Chang. 1996. Cloning and characterization of a specific coactivator, ARA70, for the androgen receptor in human prostate cells. *Proc. Natl. Acad. Sci. USA* **93:** 5517-5521.

Yuan, C.X., M. Ito, J.D. Fondell, Z.Y. Fu, and R.G. Roeder. 1998. The TRAP220 component of a thyroid hormone receptor-associated protein (TRAP) coactivator complex interacts directly with nuclear receptors in a ligand-dependent fashion. *Proc. Natl. Acad. Sci. USA* **95**: 7939-7944.

Zhang, J.J., U. Vinkemeier, W. Gu, D. Chakravarti, C.M. Horvath, and J.E.D. Jr. 1996. Two contact regions between Stat1 and CBP/p300 in interferon gamma signaling. *Proc. Natl. Acad. Sci. USA* **93**: 15092-15096.

Table 1. *Interaction of NRIF3 with nuclear receptors in yeast*

Bait	Prey	β-galactosidase activity		
		Ligand		Fold
		−	+	Stimulation
LexA	NRIF3-B42	2.3	1.9	0.8
LexA-TR	NRIF3-B42	1.8	125	69
LexA-RAR	NRIF3-B42	0.1	0.1	1
LexA-RXR	NRIF3-B42	0.2	63	315
LexA-GR	NRIF3-B42	0.8	0.6	0.8

The LacZ reporter activity was determined for yeast strains (EGY48) harboring the indicated bait and prey plasmids in the presence (+) or absence (-) of cognate ligands as described in Materials and methods. See text for detailed explanations.

Table 2. *Binding energy prediction for the interaction of the 17-residue C-terminal peptide of NRIF3 with ligand-bound LBDs of RXR, TR, and RAR*

	Hydrophobic	Electrostatic	Entropic	Total
NRIF3 / RXR	-39.3	6.7	11.4	-21.2
NRIF3 / TR	-46.5	12.4	13.2	-20.9
NRIF3 / RAR	-39.9	30.7	11.1	1.8
SRC-1 / TR	-42.0	11.3	12.6	-18.0

For each of the modeled peptide / receptor complexes, contributions by the surface (hydrophobic) term, the electrostatic term, and the entropic term were calculated as described in Materials and methods. The total binding energy was then calculated as the sum of these three terms. SRC-1 / TR was used as a control. The energy unit used in the table is kcal/mol. See text for details.

Figure legends

Figure 1. Hormone-dependent interaction of NRIF3 with the ligand binding domain (LBD) of TR. Induction of β-galactosidase activity by thyroid hormone (T3) was measured in the yeast strain EGY48 transformed with a bait vector expressing LexA-cTRα LBD and the prey plasmid expressing NRIF3 fused to the B42 activation domain (Gyuris, et al. 1993). The bait LexA alone was used as the negative control. The prey B42-Trip1 was used as the positive control.

Figure 2. Nucleotide and deduced amino acid sequences of NRIF3. Only part of the cDNA sequence is shown. A putative nuclear localization signal (KRKK) is underlined. The putative LxxLL motif is shown with a double underline. NRIF3 and the β3-endonexin long form (EnL) share 95% identity. They differ only in the C-terminus where the last 16 amino acids (dot underlined) in NRIF3 is replaced with 9 different amino acids (GQPQMSQPL) in the β3-endonexin long form. The short form of β3-endonexin consists of 111 amino acids and is 100% identical to the first 111 amino acids of NRIF3 or the β3-endonexin long form.

Figure 3. NRIF3 is a nuclear protein. HeLa cells were transfected with a expression vector for GFP (left panel) or GFP-NRIF3 (right panel). The cellular location of the expressed proteins was visualized by fluorescence microscopy.

Figure 4. Characterization of the NRIF3 interaction with nuclear receptors *in vitro*. ^{35}S-labeled full length receptor (cTRα, hRARα, hRXRα, hVDR, hPR, hGR, or hER) was incubated with affinity purified GST control or GST-NRIF3 linked to glutathione-agarose beads. The binding was performed in the absence (-) or presence (+) of cognate ligands as described in Materials and methods. After incubation and washing, the bound receptors were analyzed in 10% SDS-PAGE and detected by autoradiography. The input lane in each binding assay represents 5% of the total

^{35}S-labeled receptor used in each incubation. GST-RXR was used as a positive control for RAR binding.

Figure 5. NRIF3 enhances TR-mediated transactivation *in vivo*. HeLa cells were transfected with a vector expressing cTRα, and the IR-ΔMTV-CAT reporter (A) or the GH-TRE-tk-CAT reporter (B) in the presence (filled columns) or the absence (hatched columns) of 1 μM T3. The vector expressing NRIF3 or the empty control vector were co-transfected to examine the effect of NRIF3 on TR-mediated activation. In (A), the effect of CBP was compared to that of NRIF3.

Figure 6. NRIF3 functions as a co-activator for RXR but not RAR. (A) NRIF3 potentiates the activity of endogenous RXR(s) but not RAR(s). HeLa cells were transfected with the IR-ΔMTV-CAT reporter (without any receptor expression vector) to examine the activation by endogenous retinoid receptors. The NRIF3 expression vector or the empty control vector were co-transfected to examine the effect of NRIF3 on the activity of endogenous RXR(s) or RAR(s). Relative CAT activity was determined in the presence (filled columns) or absence (hatched columns) of indicated ligands (1 μM). (B), (C) NRIF3 potentiates the activity of exogenously expressed RXR. A vector expressing hRXRα was co-transfected into HeLa cells with the IR-ΔMTV-CAT reporter (B) or the DR1-ΔMTV-CAT reporter (C), in the presence (filled columns) or absence (hatched columns) of indicated ligands (1 μM). The effect of NRIF3 on RXR-mediated transactivation was similarly examined as in (A).

Figure 7. NRIF3 does not potentiate the activity of GR, PR, ER, or VDR. HeLa cells were transfected with the following CAT reporters and appropriate receptor expression vectors: GRE / PRE-tk-CAT and rGR or hPR (A), ERE-ΔMTV-CAT and hER (B), VDRE-ΔMTV-CAT and hVDR (C). Cells were incubated in the presence (filled columns) or absence (hatched columns) of 100 nM dexamethathone for GR, progesterone for PR, estradiol for ER, and 1,25-(OH)$_2$-VitD3

57

for VDR. Co-transfection of NRIF3 was found to have little effect on the activity of these receptors.

Figure 8. The C-terminal domain of NRIF3 is essential for the interaction with liganded TR or RXR. (A) schematic comparison of NRIF3 with EnS and EnL. EnS is 100% identical to the first 111 amino acids of NRIF3 or EnL (open box). The region from amino acid 112 to 161 is 100% identical between NRIF3 and EnL (dotted box). NRIF3 and EnL differ in their C-terminus (16 amino acids in NRIF3, hatched box; and 9 amino acids in EnL, filled box). The positions of the LxxLL motif and a putative nuclear localization signal (KRKK) are also indicated. (B) NRIF3 (N), EnS (S), or EnL (L) was examined for interaction with LexA-TR or LexA-RXR in a yeast two-hybrid assay as described in Materials and methods. The assays were performed in the absence (hatched columns) or the presence (filled columns) of 1 μM T3 (for TR) or 9-cis RA (for RXR).

Figure 9. The LxxLL motif of NRIF3 is required for optimum interaction with TR and RXR. Wild type NRIF3 (WT) or the L9A NRIF3 mutant (L9A) was examined for interaction with LexA-TR or LexA-RXR in a yeast two-hybrid assay as described in Materials and methods. β-galactosidase activities were determined in the absence (filled columns) or presence (dotted columns) of cognate ligands (1 μM T3 for TR, 1 μM 9-cis RA for RXR).

Figure 10. A structural model for the receptor specificity of NRIF3. The docking of the C-terminal helix of NRIF3 which contains an LxxIL module to the ligand-bound LBDs of RXRα, TRα, and RARα was carried out as described in Materials and methods. The side chains of the two leucines (green) and one isoleucine (cyan) of the LxxIL core fit within a hydrophobic groove on the surface of the liganded LBDs. Positively charged side chains contributed by a lysine within the LxxIL core (K173) and an arginine upstream of the core (R164) are shown in blue. Areas of negative electrostatic potential on the surfaces of the LBDs are shown in red. Specific acidic

residues of the RXR and TR LBDs that contact K173 and R164 of the NRIF3 helix are indicated

by red arrows. It was calculated that such electrostatic interactions (which are absent in the NRIF3

/ RAR model) play a major role in determining the specificity of NRIF3 (see text and Table 2 for

details).

FIGURE 1

FIGURE 2

```
  1  CAGCGGCAGTGGTGCTTTCCCGAATCTCAGAATGCCTGTTAAAAGATCACTGAAGTTGGA
                                       M  P  V  K  R  S  L  K  L  D    10

 61  TGGTCTGTTAGAAGAAAATTCATTTGATCCTTCAAAAATCACAAGGAAGAAAAGTGTTAT
      G  L  L  E  E  N  S  F  D  P  S  K  I  T  R  K  K  S  V  I    30

121  AACTTATTCTCCAACAACTGGAACTTGTCAAATGAGTCTATTTGCTTCTCCCACAAGTTC
      T  Y  S  P  T  T  G  T  C  Q  M  S  L  F  A  S  P  T  S  S    50

181  TGAAGAGCAAAAGCACAGAAATGGACTATCAAATGAAAAGAGAAAAAAATTGAATCACCC
      E  E  Q  K  H  R  N  G  L  S  N  E  K  R  K  K  L  N  H  P    70

241  CAGTTTAACTGAAAGCAAAGAATCTACAACAAAAGACAATGATGAATTCATGATGTTGCT
      S  L  T  E  S  K  E  S  T  T  K  D  N  D  E  F  M  M  L     90

301  ATCAAAAGTTGAGAAATTGTCAGAAGAAATCATGGAGATAATGCAAAATTTAAGTAGTAT
      S  K  V  E  K  L  S  E  E  I  M  E  I  M  Q  N  L  S  S  I    110

361  ACAGGCTTTGGAGGGCAGTAGAGAGCTTGAAAATCTCATTGGAATCTCCTGTGCATCACA
      Q  A  L  E  G  S  R  E  L  E  N  L  I  G  I  S  C  A  S  H    130

421  TTTCTTAAAAAGAGAAATGCAGAAAACCAAAGAACTAATGACAAAAGTGAATAAACAAAA
      F  L  K  R  E  M  Q  K  T  K  E  L  M  T  K  V  N  K  Q  K    150

481  ACTGTTTGAAAAGAGTACAGGACTTCCTCACAAAGCATCACGTCATCTTGACAGCTATGA
      L  F  E  K  S  T  G  L  P  H  K  A  S  R  H  L  D  S  Y  E    170

541  ATTCCTTAAAGCCATTTTAAAACTGAGGCATTAAGAAGAAATGCACTCACCATGAGCACCA
      F  L  K  A  I  L  N  *
```

FIGURE 3

GFP   GFP-NRIF3

FIGURE 4

FIGURE 5

A

B

FIGURE 6

FIGURE 7

FIGURE 8

FIGURE 9

FIGURE 10

RXR

TR

RAR

Rational design of novel Nuclear Hormone Receptor Antagonists

Matthieu Schapira, Bruce Raaka, Herb Samuels, and Ruben Abagyan

Abstract

Nuclear Hormone Receptors (NR) are potential therapeutic targets for many diseases, including cancer, diabetes and deregulation of brain functions. The crystal structure of the ligand binding domain of several active NR enables the design of agonists. However, with the exception of the estrogen receptor, the lack of inactive receptor structure made the rational design of antagonists impossible. In this work, we present a strategy to design such molecules: we build a model of the inactive conformation of Retinoic Acid Receptor, and use it to discover novel antagonists. The currently available crystal structures of NR can therefore be sufficient for the rational design of antagonists, which could lead to the development of novel drugs for a variety of diseases.

Introduction

The Nuclear Hormone Receptors (NR) are ligand regulated transcription factors. Members of the family are under the control of a wide variety of hormones, such as steroids, retinoids, the thyroid hormone, vitamin D or prostanoids, and many of them are potential targets for the therapy of a variety of diseases (Table 1 for references): the estrogen receptor is the receptor for tamoxyfen in breast cancer therapy, Retinoic Acid Receptor (RAR) ligands have been shown to prevent growth of certain cancer cell types and are undergoing clinical trial, Retinoid X Receptor (RXR) and Peroxysome Proliferator-Activated Receptor γ (PPARγ) ligands could be good candidates against cancer and diabetes (PPARγ is the receptor for the antidiabetic drug thiazolidinedione), Nurr1 ligands could be useful for treatment of Parkinson's disease. Designing molecules able to activate or inhibit specific NR is therefore a challenge of high medical relevance.

The crystal structure of the Ligand Binding Domain (LBD) of many members of the family has been solved during the past years, and the structural mechanism of activation is understood in great details (Moras98 for review): upon binding of an agonist, the C-terminal domain of the LBD undergoes a conformational change and closes like a lid on the ligand, thereby generating a hydrophobic pocket at the surface of the receptor. This pocket is the target for coactivator proteins which bind the LBD through a conserved LxxLL motif (Feng98, Nolte98, Darimont98). The wealth of structural information concerning this activation mechanism has made possible the design of agonists for many NR (Klaholz98, Moras98). However, until recently, nothing was known about the structure of the LBD bound to an antagonist. Two recent papers shed some light on this critical aspect of the regulation of NR metabolic pathways: the structure of the estrogen receptor LBD bound to tamoxifen and raloxifen, two antagonists, revealed at the atomic level the characteristics of the inactivated form of a receptor of the family (Brzozowski97, Shiau98). Moreover, the observation that antagonists for other NR, such as RU486 for the progesterone receptor, share some structural features with these two antagonists, suggested that the structural mechanism of receptor inactivation by antagonists could be conserved among the NR (Cadepond97, Williams98). Our goal in this work is to present a proof of concept for this hypothesis,

build a model of the antagonist-bound conformation of a member of the family unrelated to the estrogen receptor, and rationally design antagonists for this receptor.

The retinoid receptors have a critical role in the differenciation and proliferation of wide variety of cell types (Fitzgerald97, Giannini97, Chao97). Retinoic Acid Receptor (RAR) agonists were originally recognized as potential anticancer agents (Lippman87, Lippman92, Dawson95). However, serious side effects were observed and the results in the clinic were not entirely satisfactory (Hong90, Sutton97, Budd98). RAR antagonists were also recently demonstrated to be promising molecules against breast cancer (Toma98, Fanjul98), mayby through cooperation with the Retinoid X Receptor (RXR) (Westin98). The observation that RAR antagonists could induce apoptosis of both estrogen receptor positive and negative cells, and the apparent absence of undesired side effects make these compounds particularly interesting (Fanjul98). The structure of the RAR LBD bound to the natural agonist all-trans Retinoic Acid (all-trans RA) is known, but there is no information on the antagonist-bound conformation. The RAR is therefore a medically and conceptually relevant target for the design of NR antagonists, without direct information on the structure of the ligand binding site.

In the present work, we built a model of the antagonist-bound structure of RAR, based on the estrogen receptor/tamoxifen complex. The docking of two known antagonists (AGN193109 and MX781) into the modeled pocket produced excellent fit, a first indication of the validity of our model. The model was then used for the virtual screening of a database of 150000 available molecular compounds, and antagonist candidates were tested for repression of expression of a reporter gene, using an RAR-Gal4 fusion construct. Two novel antagonists and a novel agonist were discovered. The ligands were specific for RAR, confirming the validity of our model, and the medical potential of our strategy.

Modeling of the RAR antagonist binding pocket

The X-ray structure of RARγ bound to the agonist all-trans RA is available (Renaud95), however, the conformation of the receptor bound to an antagonist is not known. A first step was therefore to build a model of this complex. We used observations

made from the structure of estrogen receptor bound to an agonist, 17-β-estradiol, on one hand, and two antagonists, tamoxifen and raloxifen, on the other hand, to build this model (Brzozowski97, Shiau98).

First, agonists and antagonists superimpose well, and engage in a very similar network of hydrophobic and electrostatic contacts with the receptor. However, in the agonist-bound conformation, the C-terminal helix H12 sits like a lid on top of the ligand (Brzozowski97) (a similar observation was made for virtually all of the NR LBD structures solved so far (Moras98 for review)). On the other hand, the two antagonists present a protruding arm which is not compatible with the "closed lid" conformation (Brzozowski97, Shiau98) (Fig. 1A). As a result, helix H12 is pushed away from the hormone binding site.

Second, the two structures of the estrogen receptor bound to antagonists reveal the new localization for the C-terminal helix: it interacts with a hydrophobic groove at the surface of the receptor which coincides with the binding site of coactivator proteins, necessary for transactivation (Fig. 1B). Of particular interest is the observation that the LxxML motif of helix H12 mimics, and probably competes with, an LxxLL helical peptide of the coactivators, the signature of the members of this family. The alignment of the NR LBD (Wurtz96) shows that the helix H12 ZxxZZ motif (where Z is a hydrophobic residue) is conserved throughout the different members of the family, suggesting that it could compete with the coactivator LxxLL motif for the other NR as well. A common structural mechanism would be for the antagonists to induce the relocation of helix H12 into the hydrophobic coactivator-binding groove of the receptor. The observation that the progesterone receptor antagonist RU486 superimposes with the natural hormone progesterone, but presents a protruding arm very similar to the one of tamoxifen (Cadepond97, Williams98) is in favor of the universality of this mechanism of antagonistic activity.

To build our model, we docked helix H12 of RARγ into the putative coactivator binding pocket of the receptor as described elsewhere (Li99) (Fig.1C), and remodeled the 25 C-terminal residues, starting at the end of helix 11, through an extensive global energy minimization procedure (Fig.1D).

Docking of known antagonists into the modeled receptor

A few RAR antagonists have been described in the literature, some of which are serious candidates for cancer therapy (Toma98, Fanjul98). A well characterized ligand is AGN193109, which can bind and inhibit the 3 isoforms of RAR (RARα, RARβ and RARγ) at nanomolar concentrations (Johnson95). Another very potent antagonist recently reported is MX781, which is effective against estrogen receptor-positive and –negative breast cancer cells, with no apparent toxicity (Fanjul98). The activity of these two ligands has been presented in detail, but no structural information was reported on their mode of interaction with the receptor. We built a model of RARγ complexed either to AGN193109, or to MX781, using our flexible docking algorithm (totrov97) (Fig.2A and B). In both cases, the antagonist superimposed perfectly with the agonist all-trans RA. As observed for the estrogen receptor, the antagonists also presented a protruding arm, which was absent in agonists. Very importantly, this protruding arm coincided exactly with the single opening in the ligand binding pocket of our modeled receptor, generated by the displacement of helix H12 (Fig. 2A and B), and made stabilizing hydrophobic contacts with the protein. It is very unlikely that this perfect fit, observed for both antagonists, was fortuitous. On the contrary, this feature mimics the inactivation mechanism revealed by the crystal structure of estrogen receptor bound to tamoxifen and raloxifen. Therefore, the docking of AGN193109 and MX781 suggested very strongly that: 1) Our working hypothesis was true: the mechanism for antagonizing the estrogen receptor is transferable to other NRs. 2) Our model of the RAR antagonist binding pocket could now be used to design novel antagonists.

Screening of a virtual library and discovery of novel RAR antagonists

High throughput screening is today the most utilized method for the discovery of receptor specific ligands. This is a very efficient method, but it is also very heavy, requiring the physical availability and management of hundreds of thousands of chemical compounds. In the present work, we used a virtual library, composed of the structure (generated from their smiles sequence) of over 150000 available compounds. Each

compound was automatically docked in a grid representation of the RARα binding pocket (the RARα binding pocket was derived from our model of RARγ, where the 3 non-identical residues in the vicinity of the binding pocket –A234, M272, and A397– were mutated to the RARα isoform –S234, I272 and V397-, and energy-minimized). Five grid potentials carried information on the shape, hydrophobicity, electrostatics, and hydrogen-bonding availability of the receptor, and enabled a rapid and accurate docking simulation (Totrov99?).

153000 compounds were docked automatically to the RARα antagonist binding pocket. RARα was selected over the other two isoforms because recent data suggests it could be a medically more relevant target (Toma et al.). After an automatic selection procedure with flexible ligands, and optimization of the selected candidates with flexible protein side-chains (see Methods for details), 32 compounds were considered as potential antagonists of RARα and ordered.

To test these compounds *in vitro*, an RARα-LBD/Gal4 fusion construct was activated by the natural hormone all-trans RA, which induced the expression of a chloramphenicol acetyltransferase (CAT) reporter gene. The CAT activity was then measured, as each antagonist candidate was added to the solution. The toxicity of the compounds was deduced from the amount of cellular protein extract after 3 days. Two antagonist candidates inhibited the CAT activity by 50% at 10μM with no toxicity (Fig. 3). No inhibition was observed when CAT expression was under the control of an RXR-LBD/Gal4 fusion construct, showing that: 1) the antagonists are specific for RAR 2) the inhibition is due to interaction with the fusion construct, and not CAT (data not shown).

The two RARα antagonists dock into the ligand binding pocket of the receptor (Fig. 2C and D). As observed for AGN193109 and MX781, they superimpose well with the natural agonist all-trans RA, but present an additional protruding arm, which sticks out of the pocket. Antagonist 1 has a tri-fluoro group where the retinoid receptor ligands usually carry a carboxylate group (in Antagonist 2, the corresponding domain is troncated). An obvious way to increase the affinity of these antagonists would be to substitute the tri-fluoro group by a carboxylate in Antagonist 1, or elongate and add a carboxyalte in Antagonist2, which would engage in more stabilizing interactions with two conserved arginines of the receptor. However, the purpose of this work is to show it

is possible to rationally design antagonists from the model of the inactive receptor, and not to optimize the affinity of the compounds. The *in vitro* essays show that our modeling scheme is relevant, and can be used to design novel antagonists of NR.

Discovery of novel RARα agonists

The 32 RARα antagonist candidates were also tested experimentally for RARα agonist activity (data not shown). One of them, Agonist 1, induced activation of the CAT reporter gene at 500 nM (data not shown). This result was unexpected and interesting. Agonist 1 is much bigger than all-trans RA, which explains why it was selected as a potential antagonist (Fig. 4A and B). However, the docking of Agonist 1 into the binding pocket of active RARα shows that it can adopt a conformation where it fits very tightly into the receptor LBD and superimposes reasonably with all-trans RA (Fig 4B, right), making more extensive hydrophobic contacts with the receptor, which could explain its high affinity for RARα. Agonist 1 also has a pyridine group instead of the conserved carboxylate, and is very different from all retinoid receptor agonists described so far: it could be a very good starting point to develop novel high affinity RAR agonists.

To complete our study, we screened the virtual library for molecules which fitted into the binding pocket of the active form of RAR (the crystal structure of RARγ was used as the receptor). 30 agonist candidates were tested *in vitro* for their ability to induce CAT activity. Two compounds, Agonist 2 and Agonist 3, induced CAT activity at 1μM concentration (Fig. 4C and D). Both of these compounds were novel agonists, had the carboxylate common to all RAR ligands described in the literature, and superimposed well with all-trans RA. Agonist 1 was RAR specific, and did not activate an RXR-GAL4 fusion construct at concentrations tested (up to 20μM, data not shown), but Agonist 2 and 3 did activate both RAR and RXR.

Discussion

In this study, we presented a new strategy to discover antagonists, as well as agonists, for Nuclear Hormone Receptors, very important targets for drug design (Table 1).

An important aspect of our approach was to exclude any preconceived pharmacophore bias from our database screening. Most drug design strategies are imposing chemical constraints on the selected molecule, in order to conserve the functional groups believed to be most important in existing ligands, preventing the discovery of novel ligand types. In the present work, we avoided pharmacophore constraints due to a robust flexible docking program and scoring function: the only filters used for screening were a good fit with the receptor, and reasonable bioavailability parameters (Lipinski97). As a result, we discovered ligands with unexpected chemical and structural features, such as replacement of a conserved carboxylate by a nitro (Antagonist 2, Fig.2D) or a pyridine group (Agonist 1, Fig.4B), and unusual size (Agonist 1, Fig 4B). These novel RAR ligands present therefore valuable information for the design or optimization of RAR selective antagonists and agonists, which could have important biomedical applications.

Another important point was to demonstrate that we could discover novel antagonists for a nuclear receptor unrelated to the estrogen receptor, provided the structure of the active form of the protein was known. The retinoic acid receptor was a relevant and distant example, since, unlike the estrogen receptor, it does not belong to the steroid receptor family. Rational design of ligands from a model of the receptor is still considered today with skepticism by most professionals in the drug discovery field, and expected success rates are very low. The present study demonstrates that this strategy can be successfully undertaken with appropriate biological systems, and robust modeling tools. Moreover, targeting models of diverse members of the NR family could be further justified by the wealth of structural and sequence information (Wurtz96, Moras98), as well as a belief that the NR family members share the same mechanism of activation/inactivation (Moras98).

The recent publication of the crystal structure of medically relevant protein targets, such as PPARγ (Nolte98), RAR (Renaud95), RXR (Bourguet95), estrogen receptor (Brzozowski98) or progesterone receptor (Williams98), has created an exiting

opportunity for the discovery of novel inhibitors. This study demonstrates that the rational design of both antagonists and agonists, using computer generated models based on these structures, is possible.

Methods

Building of the model of antagonist-bound RAR

The helical peptide PLIREMLENP corresponding to helix H12 of RARγ was docked into the putative coactivator binding pocket of another RARγ molecule, as described elsewhere (li99). We hypothesized that the IxxML motif contacts the coactivator binding site, and an automatic docking procedure was carried out towards this site, with flexible protein and peptide side-chains, according to a Biased Probability Monte Carlo energy minimization procedure (Totrov94, Strynadka96). Tethers were then set between the C-terminus of the receptor and the corresponding docked helix, and the energy of the 25 C-terminal residues was minimized by a Monte Carlo sampling of the conformational space, with internal coordinates (Abagyan94).

Receptor-ligand docking

An initial docking was carried out with a grid potential representation of the receptor, and flexible ligand (Totrov97). The resulting conformation was then optimized with a full atom representation of the receptor, flexible receptor side-chains, and flexible ligand, by a double-scheme Monte Carlo energy minimization procedure (Totrov97).

Screening of a virtual library of compounds

The flexible-ligand/grid-potential-receptor docking algorithm was carried out automatically on a library of 150000 available chemical compounds. Each compound was assigned a score, according to its fit with the receptor, which took into account continuum as well as discreet electrostatics, hydrophobicity and entropy parameters (Totrov99). The best scoring compounds were further minimized with a full atom representation of the receptor, as described above.

Biological activity of the antagonist and agonist candidates

References:

Abagyan R, Totrov M. Biased probability Monte Carlo conformational searches and electrostatic calculations for peptides and proteins. J Mol Biol 1994 Jan 21;235(3):983-1002

Bischoff ED, Gottardis MM, Moon TE, Heyman RA, Lamph WW. Beyond tamoxifen: the retinoid X receptor-selective ligand LGD1069 (TARGRETIN) causes complete regression of mammary carcinoma. Cancer Res 1998 Feb 1;58(3):479-84

Bourguet W, Ruff M, Chambon P, Gronemeyer H, Moras D. Crystal structure of the ligand-binding domain of the human nuclear receptor RXR-alpha. Nature 1995 Jun 1;375(6530):377-82

Brzozowski AM, Pike AC, Dauter Z, Hubbard RE, Bonn T, Engstrom O, Ohman L, Greene GL, Gustafsson JA, Carlquist M. Molecular basis of agonism and antagonism in the oestrogen receptor. Nature 1997 Oct 16;389(6652):753-8

Budd GT, Adamson PC, Gupta M, Homayoun P, Sandstrom SK, Murphy RF, McLain D, Tuason L, Peereboom D, Bukowski RM, Ganapathi R. Phase I/II trial of all-trans retinoic acid and tamoxifen in patients with advanced breast cancer. Clin Cancer Res 1998 Mar;4(3):635-42

Cadepond F, Ulmann A, Baulieu EE. RU486 (mifepristone): mechanisms of action and clinical uses. Annu Rev Med 1997;48:129-56

Chao WR, Hobbs PD, Jong L, Zhang XK, Zheng Y, Wu Q, Shroot B, Dawson MI. Effects of receptor class- and subtype-selective retinoids and an apoptosis-inducing retinoid on the adherent growth of the NIH:OVCAR-3 ovarian cancer cell line in culture. Cancer Lett 1997 May 1;115(1):1-7

Culig Z, Hobisch A, Hittmair A, Peterziel H, Cato AC, Bartsch G, Klocker H. Expression, structure, and function of androgen receptor in advanced prostatic carcinoma. Prostate 1998 Apr 1;35(1):63-70

Darimont BD, Wagner RL, Apriletti JW, Stallcup MR, Kushner PJ, Baxter JD, Fletterick RJ, Yamamoto KR. Structure and specificity of nuclear receptor-coactivator interactions. Genes Dev 1998 Nov 1;12(21):3343-56

receptor alpha with retinoid inhibition of growth of estrogen receptor-positive MCF-7 mammary carcinoma cells. Cancer Res 1995 Oct 1;55(19):4446-51

Deeb SS, Fajas L, Nemoto M, Pihlajamaki J, Mykkanen L, Kuusisto J, Laakso M, Fujimoto W, Auwerx J. A Pro12Ala substitution in PPARgamma2 associated with decreased receptor activity, lower body mass index and improved insulin sensitivity. Nat Genet 1998 Nov;20(3):284-7

Dees EC, Kennedy MJ. Recent advances in systemic therapy for breast cancer. Curr Opin Oncol 1998 Nov;10(6):517-22

de Vos S, Dawson MI, Holden S, Le T, Wang A, Cho SK, Chen DL, Koeffler HP. Effects of retinoid X receptor-selective ligands on proliferation of prostate cancer cells. Prostate 1997 Jul 1;32(2):115-21

Eisman JA. Vitamin D receptor gene variants: implications for therapy. Curr Opin Genet Dev 1996 Jun;6(3):361-5

Elstner E, Muller C, Koshizuka K, Williamson EA, Park D, Asou H, Shintaku P, Said JW, Heber D, Koeffler HP. Ligands for peroxisome proliferator-activated receptorgamma and retinoic acid receptor inhibit growth and induce apoptosis of human breast cancer cells in vitro and in BNX mice. Proc Natl Acad Sci U S A 1998 Jul 21;95(15):8806-11

Fanjul AN, Piedrafita FJ, Al-Shamma H, Pfahl M. Apoptosis induction and potent antiestrogen receptor-negative breast cancer activity in vivo by a retinoid antagonist. Cancer Res 1998 Oct 15;58(20):4607-10

Feng W, Ribeiro RC, Wagner RL, Nguyen H, Apriletti JW, Fletterick RJ, Baxter JD, Kushner PJ, West BL. Hormone-dependent coactivator binding to a hydrophobic cleft on nuclear receptors. Science 1998 Jun 12;280(5370):1747-9

Fitzgerald P, Teng M, Chandraratna RA, Heyman RA, Allegretto EA. Retinoic acid receptor alpha expression correlates with retinoid-induced growth inhibition of human breast cancer cells regardless of estrogen receptor status. Cancer Res 1997 Jul 1;57(13):2642-50

Forman BM, Tontonoz P, Chen J, Brun RP, Spiegelman BM, Evans RM. 15-Deoxy-delta 12, 14-prostaglandin J2 is a ligand for the adipocyte determination factor PPAR gamma. Cell 1995 Dec 1;83(5):803-12

Giannini G, Dawson MI, Zhang X, Thiele CJ. Activation of three distinct RXR/RAR heterodimers induces growth arrest and differentiation of neuroblastoma cells. J Biol Chem 1997 Oct 17;272(42):26693-701

Hess RA, Bunick D, Lee KH, Bahr J, Taylor JA, Korach KS, Lubahn DB. A role for oestrogens in the male reproductive system. Nature 1997 Dec 4;390(6659):509-12

Hong WK, Lippman SM, Itri LM, Karp DD, Lee JS, Byers RM, Schantz SP, Kramer AM, Lotan R, Peters LJ, et al. Prevention of second primary tumors with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990 Sep 20;323(12):795-801

Hong WK, Sporn MB. Recent advances in chemoprevention of cancer. Science 1997 Nov 7;278(5340):1073-7

Johnson AT, Klein ES, Gillett SJ, Wang L, Song TK, Pino ME, Chandraratna RA. Synthesis and characterization of a highly potent and effective antagonist of retinoic acid receptors. J Med Chem 1995 Nov 24;38(24):4764-7

Keen RW, Kelly PJ. Genetic factors in osteoporosis. What are the implications for prevention and treatment? Drugs Aging 1997 Nov;11(5):333-7

Klaholz BP, Renaud JP, Mitschler A, Zusi C, Chambon P, Gronemeyer H, Moras D. Conformational adaptation of agonists to the human nuclear receptor RAR gamma. Nat Struct Biol 1998 Mar;5(3):199-202

Korach KS. Insights from the study of animals lacking functional estrogen receptor. Science 1994 Dec 2;266(5190):1524-7

Krege JH, Hodgin JB, Couse JF, Enmark E, Warner M, Mahler JF, Sar M, Korach KS, Gustafsson JA, Smithies O. Generation and reproductive phenotypes of mice lacking estrogen receptor beta. Proc Natl Acad Sci U S A 1998 Dec 22;95(26):15677-82

Krezel W, Ghyselinck N, Samad TA, Dupe V, Kastner P, Borrelli E, Chambon P. Impaired locomotion and dopamine signaling in retinoid receptor mutant mice. Science 1998 Feb 6;279(5352):863-7

Kubota T, Koshizuka K, Williamson EA, Asou H, Said JW, Holden S, Miyoshi I, Koeffler HP. Ligand for peroxisome proliferator-activated receptor gamma (troglitazone) has potent antitumor effect against human prostate cancer both in vitro and in vivo. Cancer Res 1998 Aug 1;58(15):3344-52

Li Y, Dawson MI, Agadir A, Lee MO, Jong L, Hobbs PD, Zhang XK. Regulation of RAR beta expression by RAR- and RXR-selective retinoids in human lung cancer cell lines: effect on growth inhibition and apoptosis induction. Int J Cancer 1998 Jan 5;75(1):88-95

Lingen MW, Polverini PJ, Bouck NP. Retinoic acid and interferon alpha act synergistically as antiangiogenic and antitumor agents against human head and neck squamous cell carcinoma. Cancer Res 1998 Dec 1;58(23):5551-8

Lipinski CA, Lombard F, Dominy BW, Feeney PJ. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Advanced Drug Delivery Reviews 1997; (23): 3-25

Lippman SM, Kessler JF, Meyskens FL Jr. Retinoids as preventive and therapeutic anticancer agents (Part I). Cancer Treat Rep 1987 Apr;71(4):391-405

Lippman SM, Kavanagh JJ, Paredes-Espinoza M, Delgadillo-Madrueno F, Paredes-Casillas P, Hong WK, Holdener E, Krakoff IH. 13-cis-retinoic acid plus interferon alpha-2a: highly active systemic therapy for squamous cell carcinoma of the cervix. J Natl Cancer Inst 1992 Feb 19;84(4):241-5

Lo Coco F, Nervi C, Avvisati G, Mandelli F. Acute promyelocytic leukemia: a curable disease. Leukemia 1998 Dec;12(12):1866-80

Moras D, Gronemeyer H. The nuclear receptor ligand-binding domain: structure and function. Curr Opin Cell Biol 1998 Jun;10(3):384-91

Mueller E, Sarraf P, Tontonoz P, Evans RM, Martin KJ, Zhang M, Fletcher C, Singer S, Spiegelman BM. Terminal differentiation of human breast cancer through PPAR gamma. Mol Cell 1998 Feb;1(3):465-70

Mukherjee R, Davies PJ, Crombie DL, Bischoff ED, Cesario RM, Jow L, Hamann LG, Boehm MF, Mondon CE, Nadzan AM, Paterniti JR Jr, Heyman RA. Sensitization of diabetic and obese mice to insulin by retinoid X receptor agonists. Nature 1997 Mar 27;386(6623):407-10

Nolte RT, Wisely GB, Westin S, Cobb JE, Lambert MH, Kurokawa R, Rosenfeld MG, Willson TM, Glass CK, Milburn MV. Ligand binding and co-activator assembly of the peroxisome proliferator-activated receptor-gamma. Nature 1998 Sep 10;395(6698):137-43

Renaud JP, Rochel N, Ruff M, Vivat V, Chambon P, Gronemeyer H, Moras D. Crystal structure of the RAR-gamma ligand-binding domain bound to all-trans retinoic acid. Nature 1995 Dec 14;378(6558):681-9

Ross RK, Pike MC, Coetzee GA, Reichardt JK, Yu MC, Feigelson H, Stanczyk FZ, Kolonel LN, Henderson BE. Androgen metabolism and prostate cancer: establishing a model of genetic susceptibility. Cancer Res 1998 Oct 15;58(20):4497-504

Saez E, Tontonoz P, Nelson MC, Alvarez JG, Ming UT, Baird SM, Thomazy VA, Evans RM. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat Med 1998 Sep;4(9):1058-61

Saltiel AR, Olefsky JM. Thiazolidinediones in the treatment of insulin resistance and type II diabetes. Diabetes 1996 Dec;45(12):1661-9

Sarraf P, Mueller E, Jones D, King FJ, DeAngelo DJ, Partridge JB, Holden SA, Chen LB, Singer S, Fletcher C, Spiegelman BM. Differentiation and reversal of malignant changes in colon cancer through PPARgamma. Nat Med 1998 Sep;4(9):1046-52

Shiau AK, Barstad D, Loria PM, Cheng L, Kushner PJ, Agard DA, Greene GL. The structural basis of estrogen receptor/coactivator recognition and the antagonism of this interaction by tamoxifen. Cell 1998 Dec 23;95(7):927-37

Shiohara M, Dawson MI, Hobbs PD, Sawai N, Higuchi T, Koike K, Komiyama A, Koeffler HP. Effects of novel RAR- and RXR-selective retinoids on myeloid leukemic proliferation and differentiation In vitro. Blood 1999 Mar 15;93(6):2057-66

Spiegelman BM. PPAR-gamma: adipogenic regulator and thiazolidinedione receptor. Diabetes 1998 Apr;47(4):507-14

Strynadka NC, Eisenstein M, Katchalski-Katzir E, Shoichet BK, Kuntz ID, Abagyan R, Totrov M, Janin J, Cherfils J, Zimmerman F, Olson A, Duncan B, Rao M, Jackson R, Sternberg M, James MN. Molecular docking programs successfully predict the binding of a beta-lactamase inhibitory protein to TEM-1 beta-lactamase. Nat Struct Biol 1996 Mar;3(3):233-9

Sutton LM, Warmuth MA, Petros WP, Winer EP. Pharmacokinetics and clinical impact of all-trans retinoic acid in metastatic breast cancer: a phase II trial. Cancer Chemother Pharmacol 1997;40(4):335-41

Tallman MS. Therapy of acute promyelocytic leukemia: all-trans retinoic acid and beyond. Leukemia 1998 Sep;12 Suppl 1:S37-40

Toma S, Isnardi L, Raffo P, Riccardi L, Dastoli G, Apfel C, LeMotte P, Bollag W. RARalpha antagonist Ro 41-5253 inhibits proliferation and induces apoptosis in breast-cancer cell lines. Int J Cancer 1998 Sep 25;78(1):86-94

Totrov M, Abagyan R. Detailed ab initio prediction of lysozyme-antibody complex with 1.6 A accuracy. Nat Struct Biol 1994 Apr;1(4):259-63

Totrov M, Abagyan R. Flexible protein-ligand docking by global energy optimization in internal coordinates. Proteins 1997;Suppl 1:215-20

Westin S, Kurokawa R, Nolte RT, Wisely GB, McInerney EM, Rose DW, Milburn MV, Rosenfeld MG, Glass CK. Interactions controlling the assembly of nuclear-receptor heterodimers and co-activators. Nature 1998 Sep 10;395(6698):199-202

Wu Q, Dawson MI, Zheng Y, Hobbs PD, Agadir A, Jong L, Li Y, Liu R, Lin B, Zhang XK. Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 1997 Nov;17(11):6598-608

Williams SP, Sigler PB. Atomic structure of progesterone complexed with its receptor. Nature 1998 May 28;393(6683):392-6

Wu Q, Dawson MI, Zheng Y, Hobbs PD, Agadir A, Jong L, Li Y, Liu R, Lin B, Zhang XK. Inhibition of trans-retinoic acid-resistant human breast cancer cell growth by retinoid X receptor-selective retinoids. Mol Cell Biol 1997 Nov;17(11):6598-608

Wurtz JM, Bourguet W, Renaud JP, Vivat V, Chambon P, Moras D, Gronemeyer H. A canonical structure for the ligand-binding domain of nuclear receptors. Nat Struct Biol 1996 Jan;3(1):87-94

Zetterstrom RH, Solomin L, Jansson L, Hoffer BJ, Olson L, Perlmann T. Dopamine neuron agenesis in Nurr1-deficient mice. Science 1997 Apr 11;276(5310):248-5

Zhang XK, Liu Y, Lee MO. Retinoid receptors in human lung cancer and breast cancer. Mutat Res 1996 Feb 19;350(1):267-77

TABLE 1

Target Receptor	Disease	References
RAR	Breast, Cervical Cancer Lung Cancer Leukemia	budd98,fanjul98,Lippm87, Lippm92 Zhang96,Li98 Shiohara99,lococo98,tallman98
RXR	Breast , Ovarian Cancer Lung, Prostate Cancer Leukemia Diabetes, Obesity	bischoff98,miller97,wu97,Chao97 Li98, deVos97 Shiohara99,lococo98,tallman98 mukherjee97
PPARγ	Diabetes, Obesity Breast, Prostate Cancer Colon Cancer	forman95,saltiel96,spiegelman98,deeb98 Elstner98,mueller98,kubota98 sarraf98
ER	Breast Cancer Infertility	dees98 kregge98,hess97,korach94
Vitamin D Receptor	Osteoporosis	keen97,eisman96
Androgen Receptor	Prostate Cancer	ross98,culig98
Nurr1	Parkinson's Disease	zetterstrom97

FIGURE 1

FIGURE 2

A AGN193109

B MX781

C Antagonist 1

D Antagonist 2

FIGURE 3

FIGURE 4

A

**B** Agonist 1

C Agonist 2

D Agonist 3

MCMR-RMI-S (70-1y)   21 Feb 03

MEMORANDUM FOR Administrator, Defense Technical Information
Center (DTIC-OCA), 8725 John J. Kingman Road, Fort Belvoir,
VA 22060-6218

SUBJECT: Request Change in Distribution Statement

1. The U.S. Army Medical Research and Materiel Command has
reexamined the need for the limitation assigned to technical
reports written for this Command. Request the limited
distribution statement for the enclosed accession numbers be
changed to "Approved for public release; distribution unlimited."
These reports should be released to the National Technical
Information Service.

2. Point of contact for this request is Ms. Kristin Morrow at
DSN 343-7327 or by e-mail at Kristin.Morrow@det.amedd.army.mil.

FOR THE COMMANDER:

Encl   PHYLIS M. RINEHART
                                  Deputy Chief of Staff for
                                    Information Management

ADB263458   ADB282838
ADB282174   ADB233092
ADB270704   ADB263929
ADB282196   ADB282182
ADB264903   ADB257136
ADB268484   ADB282227
ADB282253   ADB282177
ADB282115   ADB263548
ADB263413   ADB246535
ADB269109   ADB282826
ADB282106   ADB282127
ADB262514   ADB271165
ADB282264   ADB282112
ADB256789   ADB255775
ADB251569   ADB265599
ADB258878   ADB282098
ADB282275   ADB232738
ADB270822   ADB243196
ADB282207   ADB257445
ADB257105   ADB267547
ADB281673   ADB277556
ADB254429   ADB239320
ADB282110   ADB253648
ADB262549   ADB282171
ADB268358   ADB233883
ADB257359   ADB257696
ADB265810   ADB232089
ADB282111   ADB240398
ADB273020   ADB261087
ADB282185   ADB249593
ADB266340   ADB264542
ADB262490   ADB282216
ADB266385   ADB261617
ADB282181   ADB269116
ADB262451
ADB266306
ADB260298
ADB269253
ADB282119
ADB261755
ADB257398
ADB267683
ADB282231
ADB234475
ADB247704
ADB258112
ADB267627